<SEC-DOCUMENT>0001104659-23-126023.txt : 20231214
<SEC-HEADER>0001104659-23-126023.hdr.sgml : 20231214
<ACCEPTANCE-DATETIME>20231214160224
ACCESSION NUMBER:		0001104659-23-126023
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231212
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231214
DATE AS OF CHANGE:		20231214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Liquidia Corp
		CENTRAL INDEX KEY:			0001819576
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851710962
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39724
		FILM NUMBER:		231487055

	BUSINESS ADDRESS:	
		STREET 1:		419 DAVIS DRIVE, SUITE 100
		CITY:			MORRISVILLE
		STATE:			NC
		ZIP:			27560
		BUSINESS PHONE:		919.328.4400

	MAIL ADDRESS:	
		STREET 1:		419 DAVIS DRIVE, SUITE 100
		CITY:			MORRISVILLE
		STATE:			NC
		ZIP:			27560
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2332695d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:lqda="http://liquidia.com/20231212">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_lqda_liquidia.com_20231212 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20231212_20231212 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001819576 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:EntityCentralIndexKey">0001819576</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lqda-20231212.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-12-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-12</xbrli:startDate>
        <xbrli:endDate>2023-12-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_904_edei--DocumentType_c20231212__20231212_ztgBkI0F5Zkj"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b>December 14, 2023 </b>(<span id="xdx_90E_edei--DocumentPeriodEndDate_c20231212__20231212_zxEdIJWAx2N1"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 12, 2023</ix:nonNumeric></span>)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityRegistrantName_c20231212__20231212_z6to6qI5H7s9"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:EntityRegistrantName">LIQUIDIA CORPORATION</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact name of registrant as specified in its charter)</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; width: 34%">&#160;</td>
    <td style="text-align: center; width: 32%">&#160;</td>
    <td style="text-align: center; width: 34%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20231212__20231212_zVuyXivTwqW4"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityFileNumber_c20231212__20231212_zWKGWVQDotc3"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:EntityFileNumber">001-39724</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20231212__20231212_zIpauMAghr3a"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:EntityTaxIdentificationNumber">85-1710962</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: bottom">
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</p></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">File Number)</p></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</p></td></tr>
</table>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 32%">&#160;</td>
    <td style="width: 36%">&#160;</td>
    <td style="width: 32%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span id="xdx_901_edei--EntityAddressAddressLine1_c20231212__20231212_zFBrVNse07t" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:EntityAddressAddressLine1">419 Davis Drive</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20231212__20231212_zD5Qtw5P2247"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:EntityAddressAddressLine2">Suite 100</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_902_edei--EntityAddressCityOrTown_c20231212__20231212_z8RVWvYGJM05"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:EntityAddressCityOrTown">Morrisville</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20231212__20231212_zg4BWooPik7l"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">North Carolina</ix:nonNumeric></span></span></b></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20231212__20231212_z9broZUmAYCa"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:EntityAddressPostalZipCode">27560</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_90D_edei--CityAreaCode_c20231212__20231212_zbYA4J2UrUjj"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:CityAreaCode">919</ix:nonNumeric></span>) <span id="xdx_908_edei--LocalPhoneNumber_c20231212__20231212_z8feTbD6DBNj"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:LocalPhoneNumber">328-4400</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; text-align: center; width: 100%"><span style="font: 10pt Times New Roman, Times, Serif">(Former name or former address, if changed since last report.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90E_edei--WrittenCommunications_c20231212__20231212_zctxyNAumDx3"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span> <span style="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_906_edei--SolicitingMaterial_c20231212__20231212_zmLmrTs3BVy1"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20231212__20231212_zzF1PoZvOYzl"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20231212__20231212_zut1Ac7m24jb"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif">Title of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif">Trading Symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--Security12bTitle_c20231212__20231212_z6HmCV45cr4d"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:Security12bTitle">Common stock</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--TradingSymbol_c20231212__20231212_zRSKjfIfxn8"><ix:nonNumeric contextRef="AsOf2023-12-12" name="dei:TradingSymbol">LQDA</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">The <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--SecurityExchangeName_c20231212__20231212_zOBlMth5Hsb8"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company&#160;</span><span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20231212__20231212_z1NbOZzyp729"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityExTransitionPeriod_c20231212__20231212_zw8bSfvAjp32"><ix:nonNumeric contextRef="AsOf2023-12-12" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 3.02</b></td><td style="text-align: justify"><b>Unregistered Sale of Equity Securities</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As previously reported,
on December 12, 2023, Liquidia Corporation, a Delaware corporation (the &#8220;Company&#8221;), entered into a common stock purchase agreement
(the &#8220;Purchase Agreement&#8221;) with Roger Jeffs, the Chief Executive Officer of the Company, in connection with the previously
announced private sale of&#160;139,665 unregistered shares (the &#8220;Private Shares&#8221;) of the Company&#8217;s common stock, par
value $0.001 per share (&#8220;Common Stock&#8221;), in a private placement at a purchase price of $7.16 per share for an aggregate investment
amount of approximately $1 million (the &#8220;Private Placement&#8221;). The Private Placement closed on December 14, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The issuance of the Private
Shares in the Private Placement described above were made in reliance on the exemption from registration afforded under Section 4(a)(2)
of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and/or Rule 506 of Regulation D under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 8.01</b></td><td><b>Other Events.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As previously
reported, on December 12, 2023, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with
BofA Securities, Inc. (&#8220;Representative&#8221;), as representative of the several underwriters named therein (collectively, the
&#8220;Underwriters&#8221;), in connection with its previously announced sale of 3,491,620 shares (the &#8220;Public Shares&#8221;)
of the Company&#8217;s Common Stock, pursuant to a registration statement on Form S-3 (File No. 333-251394), filed with the United
States Securities and Exchange Commission (the &#8220;SEC&#8221;) on December 16, 2020, and which was declared effective by the SEC
on December 23, 2020, and the prospectus contained therein, as supplemented by the prospectus supplement dated December 12, 2023
(the &#8220;Prospectus Supplement&#8221;), in an underwritten registered public offering at an offering price of $7.16 per Public
Share (the &#8220;Offering&#8221;) for gross proceeds of approximately $25 million (before deducting underwriting discounts,
commissions and expenses). The Offering closed on December 14, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Copies of the
Underwriting Agreement and the Purchase Agreement are attached as Exhibits 1.1 and 10.1 hereto, respectively, and are each
incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and the Purchase Agreement do not purport
to be complete and are qualified in their entirety by reference to such exhibits, respectively. The provisions of the Underwriting
Agreement and the Purchase Agreement, including the representations and warranties contained therein, respectively, are not for the
benefit of any party other than the parties to such agreement, respectively, and are not intended as a document for investors and
the public to obtain factual information about the current state of affairs of the Company. Rather, investors and the public should
look to other disclosures contained in the Company&#8217;s filings with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A copy of the legal opinion
and consent of DLA Piper LLP (US) relating to the Offering is attached as Exhibit 5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br />
    No.</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td><a href="tm2332695d2_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2332695d2_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement
    by and between Liquidia Corporation and BofA Securities, Inc., as representative of the underwriters named therein, dated December
    12, 2023.</span></a></td></tr>
  <tr>
    <td><a href="tm2332695d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2332695d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of DLA Piper LLP
    (US).</span></a></td></tr>
  <tr>
    <td><a href="tm2332695d2_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2332695d2_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Agreement by and
    between Liquidia Corporation and Roger Jeffs, dated December 12, 2023.</span></a></td></tr>
  <tr>
    <td><a href="tm2332695d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2332695d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of DLA Piper LLP
    (US) (included in Exhibit 5.1).</span></a></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (the cover page tags are embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline">SIGNATURES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 14, 2023</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidia Corporation</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael Kaseta</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Michael Kaseta</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: &#160;&#160;Chief Financial Officer</p></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LG4rDmGPDhVxiowhvlaXSXFrRlqnfpJ/ad0QQyAkN+deISZiTSvdIMNpUeRQYts1yiEUWCOjuaD/yDbbFPws8KqtY2XcsP7AjDyDnkmmydnfh89eW6xSiONQzkIZQTRPpYTDTgRfPSNT6wqN06oBZSo4MHWs0Sl+jQ6lepKh9jUkHZGtJuPtptEov0FGsYQ99epBfLOQ55kIJkMFYs10774xd+uohWWDrc+yI/rv4APci0kX -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2332695d2_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3,491,620 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Liquidia Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>UNDERWRITING AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 1in">December&nbsp;12, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As Representative of the several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Introductory.
</B></FONT>Liquidia Corporation, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several
underwriters named in <U>Schedule A</U> (the &ldquo;<B>Underwriters</B>&rdquo;) an aggregate of 3,491,620 shares of its common stock,
par value $0.001 per share (the &ldquo;<B>Shares</B>&rdquo;). The 3,491,620 Shares to be sold by the Company are called the &ldquo;<B>Offered
Shares</B>.&rdquo; BofA Securities,&nbsp;Inc. (&ldquo;<B>BofA</B>&rdquo;) has agreed to act as representative of the several Underwriters
(in such capacity, the &ldquo;<B>Representative</B>&rdquo;) in connection with the offering and sale of the Offered Shares. To the extent
there are no additional underwriters listed on <U>Schedule A</U>, the term &ldquo;Representative&rdquo; as used herein shall mean you,
as Underwriter, and the term &ldquo;Underwriters&rdquo; shall mean either the singular or the plural, as the context requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company has prepared and
filed with the U.S. Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a shelf registration statement on Form&nbsp;S-3,
File No.&nbsp;333-251394, including a base prospectus (the &ldquo;<B>Base Prospectus</B>&rdquo;) to be used in connection with the public
offering and sale of the Offered Shares. Such registration statement, as amended, including the financial statements, exhibits and schedules
thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated
thereunder (collectively, the &ldquo;<B>Securities Act</B>&rdquo;), including all documents incorporated or deemed to be incorporated
by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A or Rule&nbsp;430B
under the Securities Act, is called the &ldquo;<B>Registration Statement</B>.&rdquo; Any registration statement filed by the Company
pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act in connection with the offer and sale of the Offered Shares is called the
 &ldquo;<B>Rule&nbsp;462(b)&nbsp;Registration Statement</B>,&rdquo; and from and after the date and time of filing of any such Rule&nbsp;462(b)&nbsp;Registration
Statement the term &ldquo;Registration Statement&rdquo; shall include the Rule&nbsp;462(b)&nbsp;Registration Statement. Each preliminary
prospectus supplement used in connection with the offering of the Offered Shares, if any, including the Base Prospectus and the documents
incorporated or deemed to be incorporated by reference therein, are collectively referred to herein as a &ldquo;<B>preliminary prospectus</B>.&rdquo;
As used herein, the term &ldquo;<B>Prospectus</B>&rdquo; shall mean the final prospectus supplement to the Base Prospectus that describes
the Offered Shares and the offering thereof (the &ldquo;<B>Final Prospectus Supplement</B>&rdquo;), together with the Base Prospectus
in the form first used by the Underwriters to confirm sales of the Offered Shares or in the form first made available to the Underwriters
by the Company to meet requests of purchasers pursuant to Rule&nbsp;173 under the Securities Act. References herein to any preliminary
prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components of such prospectus. As
used herein, the &ldquo;<B>Applicable Time</B>&rdquo; is 7:15 a.m.&nbsp;(New York City time) on December&nbsp;12, 2023. As used herein,
 &ldquo;<B>free writing prospectus</B>&rdquo; has the meaning set forth in Rule&nbsp;405 under the Securities Act, and &ldquo;<B>Time
of Sale Prospectus</B>&rdquo; means the Base Prospectus, as amended or supplemented immediately prior to the Applicable Time, together
with the free writing prospectuses, if any, identified in <U>Schedule B</U> hereto and the pricing information set forth on <U>Schedule
B</U> hereto. As used herein, <B>&ldquo;Road Show&rdquo; </B>means a &ldquo;road show&rdquo; (as defined in Rule&nbsp;433 under the Securities
Act) relating to the offering of the Offered Shares contemplated hereby that is a &ldquo;written communication&rdquo; (as defined in
Rule&nbsp;405 under the Securities Act). As used herein, &ldquo;<B>Marketing Materials</B>&rdquo; means any materials or information
provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Shares,
including any roadshow or investor presentations made to investors by the Company (whether in person or electronically) listed on <U>Schedule
C</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All references in this Agreement
to the Registration Statement, any preliminary prospectus, the Base Prospectus and the Prospectus shall include the documents incorporated
or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules and other information
which are &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo; in, or &ldquo;part of&rdquo; the Registration Statement,
the Rule&nbsp;462(b)&nbsp;Registration Statement, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the
Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules
and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Rule&nbsp;462(b)&nbsp;Registration
Statement, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All references in this Agreement
to amendments or supplements to the Registration Statement, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus
or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended,
and the rules&nbsp;and regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;) that is or is deemed
to be incorporated by reference in the Registration Statement, any preliminary prospectus, the Base Prospectus, or the Prospectus, as
the case may be. All references in this Agreement to (i)&nbsp;the Registration Statement, any preliminary prospectus, the Base Prospectus
or the Prospectus, any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof
filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&ldquo;<B>EDGAR</B>&rdquo;) and (ii)&nbsp;the
Prospectus shall be deemed to include any &ldquo;electronic Prospectus&rdquo; provided for use in connection with the offering of the
Offered Shares as contemplated by Section&nbsp;3(n)&nbsp;of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company hereby confirms
its agreements with the Underwriters as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Representations
and Warranties</B></FONT>. The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement
and as of the Closing Date (as hereinafter defined) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Compliance
with Registration Requirements</I>. </B>Each of the Registration Statement and any post-effective amendment thereto has become effective
under the Securities Act. The Company has complied, to the Commission&rsquo;s satisfaction with all requests of the Commission for additional
or supplemental information, if any. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto is in effect and no proceedings for such purpose or pursuant to Section&nbsp;8A under the Securities Act have been instituted
or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission. At the time the Company&rsquo;s
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2022 (the &ldquo;<B>Annual Report</B>&rdquo;) was filed with the
Commission, or, if later, at the time the Registration Statement was originally filed with the Commission, the Company met the then-applicable
requirements for use of Form&nbsp;S-3 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Disclosure</I>.
</B>Each preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities Act and, if filed
by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation S-T under the Securities Act) to
the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Shares. Each of the Registration
Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material
respects with the applicable requirements of the Securities Act and did not and will not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the
Applicable Time, the Time of Sale Prospectus did not, and at the Closing Date (as defined in Section&nbsp;2 of this Agreement) will not,
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading. The Prospectus, as of its date, did not, and at the Closing Date will
not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three
immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment
thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity
with written information relating to any Underwriter furnished to the Company in writing by the Representative expressly for use therein,
it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b)&nbsp;below.
The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Time of Sale Prospectus, each
preliminary prospectus and the Prospectus, at the time the Registration Statement became effective or at the time they were or hereafter
are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply in all material
respects with the requirements of the Exchange Act and did not and will not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading. There are no contracts
or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration
Statement which have not been described or filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Free
Writing Prospectuses; Road Show</I>. </B>As of the determination date referenced in Rule&nbsp;164(h)&nbsp;under the Securities Act, the
Company was not, is not or will not be (as applicable) an &ldquo;ineligible issuer&rdquo; in connection with the offering of the Offered
Shares pursuant to Rules&nbsp;164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company is required to
file pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act has been, or will be, filed with the Commission in accordance with the
requirements of the Securities Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material
respects with the requirements of Rule&nbsp;433 under the Securities Act, including timely filing with the Commission or retention where
required and legending, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion
of the public offer and sale of the Offered Shares did not, does not and will not include any information that conflicted, conflicts
or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus unless such
information has been superseded or modified as of such time. Except for the free writing prospectuses, if any, identified in <U>Schedule
B</U>, and electronic road shows, if any, furnished to the Representative before first use, the Company has not prepared, used or referred
to, and will not, without the Representative&rsquo;s prior written consent, prepare, use or refer to, any free writing prospectus. Each
Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Distribution
of Offering Material By the Company</I>. </B>Prior to the later of (i)&nbsp;the expiration or termination of the option granted to the
several Underwriters in Section&nbsp;2 of this Agreement, and (ii)&nbsp;the completion of the Underwriters&rsquo; distribution of the
Offered Shares, the Company has not distributed and will not distribute any offering material in connection with the offering and sale
of the Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus
reviewed and consented to by the Representative, the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto and any
Marketing Materials identified on <U>Schedule C</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>The
Underwriting Agreement</I>. </B>This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Authorization
of the Offered Shares</I>. </B>The Offered Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when
issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable,
and the issuance and sale of the Offered Shares is not subject to any preemptive rights, rights of first refusal or other similar rights
to subscribe for or purchase the Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>No
Applicable Registration or Other Similar Rights</I>. </B>There are no persons with registration or other similar rights to have any equity
or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except
for such rights as have been duly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>No
Material Adverse Change</I>. </B>Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the
Prospectus: (i)&nbsp;there has been no material adverse change, or any development that would be reasonably expected to result in a material
adverse change, in the condition, financial or otherwise, or in the earnings, business, properties, operations, assets, liabilities or
prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered
as one entity (any such change being referred to herein as a &ldquo;<B>Material Adverse Change</B>&rdquo;); (ii)&nbsp; the Company and
its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including
without limitation any losses or interference with its business from fire, explosion, flood, earthquakes, accident or other calamity,
whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material,
individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions
(whether or not in the ordinary course of business) that are material to the Company and its subsidiaries, considered as one entity;
and (iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term
indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by
the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&rsquo;s subsidiaries on any class
of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Independent
Accountants</I>. </B>PricewaterhouseCoopers LLP, which has expressed its opinion with respect to the financial statements (which term
as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the
Time of Sale Prospectus and the Prospectus, is (i)&nbsp;an independent registered public accounting firm as required by the Securities
Act and the rules&nbsp;of the Public Company Accounting Oversight Board (&ldquo;<B>PCAOB</B>&rdquo;), (ii)&nbsp;in compliance with the
applicable requirements relating to the qualification of accountants under Rule&nbsp;2-01 of Regulation S-X under the Securities Act
and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who
has not requested such registration to be withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Financial
Statements</I>. </B>The financial statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus
and the Prospectus present fairly in all material respects the consolidated financial position of the Company and its subsidiaries as
of the dates indicated and the results of their operations, changes in stockholders&rsquo; equity and cash flows for the periods specified.
Such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States
applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. No other
financial statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or
the Prospectus. The financial data set forth in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus under
the caption &ldquo;Selected Financial Data&rdquo; fairly present in all material respects the information set forth therein on a basis
consistent with that of the audited financial statements contained in the Registration Statement, the Time of Sale Prospectus and the
Prospectus. To the Company&rsquo;s knowledge, no person who has been suspended or barred from being associated with a registered public
accounting firm, or who has failed to comply with any sanction pursuant to Rule&nbsp;5300 promulgated by the PCAOB, has participated
in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with
the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus. The interactive data in eXtensible
Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called
for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Company&rsquo;s
Accounting System</I>. </B>The Company and each of its subsidiaries make and keep accurate books and records and maintain a system of
internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s
general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii)&nbsp;access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization; (iv)&nbsp;the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration
Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and has
been prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Disclosure
Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</I>. </B>The Company has established
and maintains disclosure controls and procedures (as defined in Rules&nbsp;13a-15 and 15d-15 under the Exchange Act), which (i)&nbsp;are
designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&rsquo;s
principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which
the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for
effectiveness as of the end of the Company&rsquo;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects
to perform the functions for which they were established. Since the end of the Company&rsquo;s most recent audited fiscal year, there
have been no significant deficiencies or material weakness in the Company&rsquo;s internal control over financial reporting (whether
or not remediated) and no change in the Company&rsquo;s internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting. The Company is not aware of any
change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected,
or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Incorporation
and Good Standing of the Company</I>. </B>The Company has been duly incorporated and is validly existing as a corporation in good standing
under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties
and to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into
and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is
in good standing in the State of North Carolina and each other jurisdiction in which such qualification is required, whether by reason
of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in good standing could
not reasonably be expected individually or in the aggregate to have a material adverse effect on the condition (financial or other),
earnings, business, properties, operations, assets, liabilities or prospects of the Company and its subsidiaries, taken as a whole (a
 &ldquo;<B>Material Adverse Effect</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Subsidiaries</I>.
</B>Each of the Company&rsquo;s &ldquo;subsidiaries&rdquo; (for purposes of this Agreement, as defined in Rule&nbsp;405 under the Securities
Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability
company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and
authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus. Each of the Company&rsquo;s subsidiaries is duly qualified as a foreign corporation,
partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such
qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure
to be so qualified or in good standing could not be reasonably expected individually or in the aggregate to have a Material Adverse Effect.
All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&rsquo;s subsidiaries have
been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries,
free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the outstanding capital stock
or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary.
The constitutive or organizational documents of each of the subsidiaries comply in all material respects with the requirements of applicable
laws of its jurisdiction of incorporation or organization and are in full force and effect. The Company does not own or control, directly
or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit&nbsp;21.1 to the Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Capitalization
and Other Capital Stock Matters</I>. </B>The authorized, issued and outstanding capital stock of the Company as of September&nbsp;30,
2023 is as set forth in the Company&rsquo;s unaudited financial statements contained in the Company&rsquo;s Quarterly Report on Form&nbsp;10-Q
filed with the Commission on November&nbsp;7, 2023, which is incorporated by reference in the Registration Statement, the Time of Sale
Prospectus and the Prospectus (other than for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise
of outstanding options or warrants, in each case described in the Registration Statement, the Time of Sale Prospectus and the Prospectus).
The Shares (including the Offered Shares, when issued pursuant to the terms of this Agreement) conform in all material respects to the
description thereof contained in the Time of Sale Prospectus. All of the issued and outstanding Shares have been duly authorized and
validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None
of the outstanding Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe
for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first
refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock
of the Company or any of its subsidiaries other than those described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus. The descriptions of the Company&rsquo;s stock option, stock bonus and other stock plans or arrangements, and the options
or other rights granted thereunder, set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately
and fairly presents the information required to be shown with respect to such plans, arrangements, options and rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Stock
Exchange Listing</I></B>. The Shares are registered pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act and are listed on The Nasdaq
Capital Market (&ldquo;<B>Nasdaq</B>&rdquo;), and the Company has taken no action designed to, or likely to have the effect of, terminating
the registration of the Shares under the Exchange Act or delisting the Shares from Nasdaq, nor has the Company received any notification
that the Commission or Nasdaq is contemplating terminating such registration or listing. To the Company&rsquo;s knowledge, it is in compliance
with all applicable listing requirements of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Non-Contravention
of Existing Instruments; No Further Authorizations or Approvals Required</I>. </B>Neither the Company nor any of its subsidiaries is
in violation of its charter or by- laws, or similar organizational documents, as applicable, or is in default (or, with the giving of
notice or lapse of time, would be in default) (&ldquo;<B>Default</B>&rdquo;) under any indenture, loan, credit agreement, note, lease,
license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement,
mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any
of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are
subject (each, an &ldquo;<B>Existing Instrument</B>&rdquo;), except for such Defaults as would reasonably not be expected, individually
or in the aggregate, to have a Material Adverse Effect. The Company&rsquo;s execution, delivery and performance of this Agreement, consummation
of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus and the issuance
and sale of the Offered Shares (including the use of proceeds from the sale of the Offered Shares as described in the Registration Statement,
the Time of Sale Prospectus and the Prospectus under the caption &ldquo;Use of Proceeds&rdquo;) (i)&nbsp;have been duly authorized by
all necessary corporate action and will not result in any violation of the provisions of the charter or by-laws, or similar organizational
documents, as applicable, of the Company or any subsidiaries, (ii)&nbsp;will not conflict with or constitute a breach of, or Default
or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance
upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any
Existing Instrument, except as could reasonably not be expected, individually or in the aggregate, to have a Material Adverse Effect,
and (iii)&nbsp;will not result in any violation of any law, administrative regulation or administrative or court decree applicable to
the Company or any of its subsidiaries. No consent, approval, authorization or other order of, or registration or filing with, any court
or other governmental or regulatory authority or agency, is required for the Company&rsquo;s execution, delivery and performance of this
Agreement and consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and
the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and
such as may be required under applicable state securities or blue sky laws or the Financial Industry Regulatory Authority,&nbsp;Inc.
(&ldquo;<B>FINRA</B>&rdquo;). As used herein, a &ldquo;<B>Debt Repayment Triggering Event</B>&rdquo; means any event or condition which
gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness
(or any person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or a portion
of such indebtedness by the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Compliance
with Laws. </I></B>The Company and its subsidiaries have been and are in compliance with all applicable laws, rules&nbsp;and regulations,
except where failure to be so in compliance would reasonably not be expected, individually or in the aggregate, to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>No
Material Actions or Proceedings</I>. </B>Except as disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus,
(i)&nbsp;there is no action, suit, proceeding, inquiry or investigation brought by or before any governmental entity now pending or,
to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which would be reasonably expected,
individually or in the aggregate, to have a Material Adverse Effect or materially and adversely affect the consummation of the transactions
contemplated by this Agreement or the performance by the Company of its obligations hereunder; and (ii)&nbsp;the aggregate of all pending
legal or governmental proceedings to which the Company is a party or of which its properties or assets is the subject, including ordinary
routine litigation incidental to the business, if determined adversely to the Company or any of its subsidiaries, would not reasonably
be expected to have a Material Adverse Effect. No material labor dispute with the employees of the Company, or with the employees of
any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened
or imminent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Intellectual
Property Rights</I>. </B>Except as disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus, the Company
and its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks,
trade names, service marks, registered and unregistered copyrights , trade secrets, logos, slogans, trade dress, design rights,&nbsp;Internet
domain names, social media accounts, intellectual property rights in technology, software, source code, data and know how (including
unpatented and/or unpatentable proprietary or confidential information, systems or procedures), and any applications (including provisional
applications), registrations, or renewals for any of the foregoing, together with the goodwill associated with any of the foregoing,
and other intellectual property described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned
or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or as currently proposed
to be conducted, in each case as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus (collectively,
 &ldquo;<B>Intellectual Property</B>&rdquo;), except for such exceptions as could not be expected, individually or in the aggregate, to
have a Material Adverse Effect. To the Company&rsquo;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual
Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in
the Registration Statement, the Time of Sale Prospectus and the Prospectus as licensed to the Company or one or more of its subsidiaries;
and (ii)&nbsp;there is no infringement, misappropriation, dilution or other violation by third parties of any Intellectual Property.
Except as disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus, there is no pending or, to the Company&rsquo;s
knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&rsquo;s rights in or to any Intellectual
Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim;
(B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which
would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or any of its subsidiaries
infringes, misappropriates, dilutes or otherwise violates, or would, upon the commercialization of any product or service described in
the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe, misappropriate, dilute or violate,
any patent, trademark, trade name, service name, copyright, trade secret or other intellectual property rights of others, and the Company
has not received any notice or is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim.
Except as disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus, no government funding, facilities or
resources of a university, college, other educational institution or research center was used in the development of any Intellectual
Property that is owned or purported to be owned by the Company that would confer any governmental agency or body, university, college,
other educational institution or research center any claim or right of ownership to any such Intellectual Property. Except as disclosed
in the Registration Statement, the Time of Sale Prospectus or the Prospectus, the Company is not obligated to pay a material royalty,
grant a license or option, or provide other material consideration to any third party in connection with the Intellectual Property. The
Company and its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property
has been licensed to the Company or any subsidiary, and all such agreements are in full force The Company and its subsidiaries have taken
commercially reasonable steps to protect, maintain and safeguard the Intellectual Property. The product candidates described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus as under development by the Company or any subsidiary fall within the scope
of the claims of one or more patents or patent applications owned by, or exclusively licensed to, the Company or any subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>All
Necessary Permits,&nbsp;etc</I>. </B>The Company and its subsidiaries possess such valid and current certificates, clearances, approvals,
exemptions, registrations, authorizations and permits required by state, federal or foreign regulatory agencies or bodies to conduct
their respective businesses as currently conducted and as described in the Registration Statement, the Time of Sale Prospectus or the
Prospectus (&ldquo;<B>Permits</B>&rdquo;), except where the failure to possess such Permit as would not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect. Except as would not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect: (i)&nbsp;all such Permits are in full force and effect; (ii)&nbsp;neither the Company nor any of its
subsidiaries is in violation of any term of, or in default under, any of the Permits nor has received any notice of proceedings relating
to the revocation or modification of, or non-compliance with, any such Permit; and (iii)&nbsp;to the Company&rsquo;s knowledge, no event
has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other material
impairment of the rights of the holder of any such Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Title
to Properties</I>. </B>Neither the Company nor its subsidiaries own real property. The Company and its subsidiaries have good and marketable
title to all of the personal property and other assets reflected as owned in the financial statements referred to in Section&nbsp;1(j)&nbsp;above
(or elsewhere in the Registration Statement, the Time of Sale Prospectus or the Prospectus), in each case free and clear of any security
interests, mortgages, liens, encumbrances, equities, adverse claims and other defects. The real property, improvements, equipment and
personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions
as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment
or personal property by the Company or such subsidiary. The representations and warranties contained in this Section&nbsp;1(v)&nbsp;do
not apply to any matter the subject matter of which is specifically covered by Section&nbsp;1(t)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Tax
Law Compliance</I>. </B>The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise Tax
returns or have properly requested extensions thereof and have paid all Taxes required to be paid by any of them and, if due and payable,
any related or similar assessment, fine or penalty levied against any of them except (i)&nbsp;as may be being contested in good faith
and by appropriate proceedings with adequate reserves set aside in accordance with GAAP or (ii)&nbsp;as would not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect. The Company has made adequate charges, accruals and reserves in
the applicable financial statements referred to in Section&nbsp;1(j)&nbsp;above in respect of all federal, state and foreign income,
franchise and other Taxes for all periods as to which the Tax liability of the Company or any of its subsidiaries has not been finally
determined. For purposes of this Agreement, the term &ldquo;Tax&rdquo; and &ldquo;Taxes&rdquo; shall mean all U.S. and non-U.S. federal,
state, local and franchise taxes, and other assessments of a similar nature (whether imposed directly or through withholding), including
any interest, additions to tax or penalties applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Insurance</I>.
</B>Each of the Company and its subsidiaries are insured by recognized, financially sound and reputable institutions with policies in
such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses, in
the reasonable judgement of the Company&rsquo;s Board of Directors, for its business including, but not limited to, policies covering
real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism
and earthquakes and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability claims.
The Company has no reason to believe that it or any of its subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage
as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate
to conduct its business as now conducted and at a cost that would not reasonably be expected to have a Material Adverse Effect. Neither
the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Compliance
with Environmental Laws</I>. </B>Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect: (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law,
rule, regulation, ordinance, code, policy or rule&nbsp;of common law or any judicial or administrative interpretation thereof, including
any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment
(including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without
limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic
substances, hazardous substances, petroleum or petroleum products (collectively, &ldquo;<B>Hazardous Materials</B>&rdquo;) or to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively,
 &ldquo;<B>Environmental Laws</B>&rdquo;); (ii)&nbsp;the Company and its subsidiaries have all permits, authorizations and approvals required
under any applicable Environmental Laws and are each in compliance with their requirements; (iii)&nbsp;there are no pending or, to the
Company&rsquo;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens,
notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its
subsidiaries; and (iv)&nbsp;to the Company&rsquo;s knowledge, there are no events or circumstances existing as of the date hereof that
might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private
party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or
any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>ERISA
Compliance</I>. </B>The Company and its subsidiaries and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement
Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;<B>ERISA</B>&rdquo;))
established or maintained by the Company, its subsidiaries or their &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance
in all material respects with ERISA. &ldquo;<B>ERISA Affiliate</B>&rdquo; means, with respect to the Company or any of its subsidiaries,
any member of any group of organizations described in Sections 414(b), (c), (m)&nbsp;or (o)&nbsp;of the Internal Revenue Code of 1986,
as amended, and the regulations and published interpretations thereunder (the &ldquo;<B>Code</B>&rdquo;) of which the Company or such
subsidiary is a member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to occur with
respect to any &ldquo;employee benefit plan&rdquo; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates.
No &ldquo;employee benefit plan&rdquo; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if
such &ldquo;employee benefit plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined
under ERISA). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any liability under (i)&nbsp;Title
IV of ERISA with respect to termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo; or (ii)&nbsp;Sections 412, 4971,
4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA
Affiliates that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified and nothing has occurred, whether
by action or failure to act, which would cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Company
Not an &ldquo;Investment Company.&rdquo; </I></B>The Company is not, and will not be, either after receipt of payment for the Offered
Shares or after the application of the proceeds therefrom as described under &ldquo;Use of Proceeds&rdquo; in the Registration Statement,
the Time of Sale Prospectus or the Prospectus, required to register as an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo;
by an &ldquo;investment company&rdquo; under the Investment Company Act of 1940, as amended and the rules&nbsp;and regulations of the
Commission thereunder (collectively, the &ldquo;<B>Investment Company Act</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>No
Price Stabilization or Manipulation; Compliance with Regulation M</I>. </B>Neither the Company nor any of its subsidiaries has taken,
directly or indirectly, any action designed to or that would reasonably be expected to cause or result in stabilization or manipulation
of the price of the Shares or of any &ldquo;reference security&rdquo; (as defined in Rule&nbsp;100 of Regulation M under the Exchange
Act (&ldquo;<B>Regulation M</B>&rdquo;)) with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or
otherwise, and has taken no action which would directly or indirectly violate Regulation M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Related-Party
Transactions</I>. </B>There are no business relationships or related-party transactions involving the Company or any of its subsidiaries
or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not
been described as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>FINRA
Matters.</I></B> All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel,
its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in
connection with the offering of the Offered Shares is true, complete, correct and compliant with FINRA&rsquo;s rules&nbsp;and any letters,
filings or other supplemental information provided to FINRA pursuant to FINRA Rules&nbsp;is true, complete and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Parties
to Lock-Up Agreements.</I></B> The Company has furnished to the Underwriters a letter agreement substantially in the form attached hereto
as <U>Exhibit&nbsp;A</U> (the &ldquo;<B>Lock-up Agreement</B>&rdquo;) from each of the persons listed on <U>Exhibit&nbsp;B</U>. Such
<U>Exhibit&nbsp;B</U> lists under an appropriate caption the directors and officers of the Company. If any additional persons shall become
directors or officers (as defined in Rule&nbsp;16a-1(f)&nbsp;under the Exchange Act) of the Company prior to the end of the Company Lock-up
Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election
as a director or officer of the Company, to execute and deliver to the Representative a Lock-up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Statistical
and Market-Related Data.</I></B> All statistical, demographic and market- related data included in the Registration Statement, the Time
of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be
reliable and accurate. To the extent required, the Company has obtained the written consent to the use of such data from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>No
Unlawful Contributions or Other Payments.</I></B> Neither the Company nor any of its subsidiaries nor, to the best of the Company&rsquo;s
knowledge, any director, officer or employee or agent of the Company or any subsidiary, has made any contribution or other payment to
any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed
in the Registration Statement, the Time of Sale Prospectus or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Foreign
Corrupt Practices Act.</I></B> Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer,
agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions
for, or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment
or other unlawful expenses relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment to any domestic government
official, &ldquo;foreign official&rdquo; (as defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules&nbsp;and
regulations thereunder (collectively, the &ldquo;<B>FCPA</B>&rdquo;) or employee from corporate funds; (iii)&nbsp;violated or is in violation
of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation; or (iv)&nbsp;made any unlawful bribe, rebate,
payoff, influence payment, kickback or other unlawful payment to any domestic government official, such foreign official or employee;
and the Company and its subsidiaries and, to the knowledge of the Company, the Company&rsquo;s affiliates have conducted their respective
businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably
expected to continue to ensure, continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Money
Laundering Laws.</I></B> The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all applicable jurisdictions, the rules&nbsp;and regulations thereunder and any related or
similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &ldquo;<B>Money
Laundering Laws</B>&rdquo;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge
of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Sanctions.
</I></B>Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, after due inquiry, any director, officer,
agent, employee, affiliate or person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target
of any sanctions administered or enforced by the U.S. government, including, without limitation, the Office of Foreign Assets Control
of the U.S. Department of the Treasury (&ldquo;<B>OFAC</B>&rdquo;) or the U.S. Department of State, which includes, without limitation,
the designation as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person,&rdquo; the United Nations Security Council,
the European Union, His Majesty&rsquo;s Treasury of the United Kingdom or other relevant sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;);
nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target
of Sanctions, including, without limitation, the Crimea Region of Ukraine, the so-called Donetsk People&rsquo;s Republic, the so-called
Luhansk People&rsquo;s Republic, Cuba,&nbsp;Iran, North Korea and Syria, (each, a &ldquo;<B>Sanctioned Country</B>&rdquo;); and the Company
will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any
subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any
person, or in any country or territory that, at the time of such financing, is the subject or the target of Sanctions or in any other
manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor,
investor or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged
in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is
or was the subject or the target of Sanctions or with any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Brokers.
</I></B>Except pursuant to this Agreement, there is no broker, finder or other party that is entitled to receive from the Company any
brokerage or finder&rsquo;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Forward-Looking
Statements.</I></B> Each financial or operational projection or other &ldquo;forward-looking statement&rdquo; (as defined by Section&nbsp;27A
of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or
the Prospectus (i)&nbsp;was so included by the Company in good faith and with reasonable basis after due consideration by the Company
of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary
statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statement.
No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Emerging
Growth Company Status.</I></B> From the time of the Company&rsquo;s initial public offering of its Shares through the date hereof, the
Company has been and is an &ldquo;emerging growth company,&rdquo; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act (an &ldquo;<B>Emerging
Growth Compan</B>y&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>[Reserved].</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Clinical
Data and Regulatory Compliance.</I></B> The preclinical tests and clinical trials, and other studies (collectively, &ldquo;<B>Studies</B>&rdquo;)
that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus
were and, if still pending, are being conducted in all material respects in accordance with all applicable Health Care Laws; each description
of the results of such Studies is accurate and complete in all material respects and fairly presents the data derived from such Studies,
and the Company has no knowledge of any other Studies the results of which are materially inconsistent with, or otherwise call into question,
the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company and
its subsidiaries have made all such filings and obtained all such approvals or exemptions or other Permits as may be required by the
U.S. Food and Drug Administration (the &ldquo;<B>FDA</B>&rdquo;) or any committee thereof or from any other U.S. or foreign government
or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the &ldquo;<B>Regulatory
Agencies</B>&rdquo;) for the conduct of any such Studies; neither the Company nor any of its subsidiaries has received any notice of,
or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any Studies that are described
or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have
each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory
Agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Compliance
with Health Care Laws.</I></B> The Company and its subsidiaries are, and at all times have been, in material compliance with all applicable
Health Care Laws. For purposes of this Agreement, &ldquo;<B>Health Care Laws</B>&rdquo; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic
Act and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care laws, including,
without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section&nbsp;1320a-7b(b)), the Civil Monetary Penalties Law (42 U.S.C.
Section&nbsp;1320a-7a), the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), all applicable federal, state, local and
all foreign criminal laws relating to health care fraud and abuse, including but not limited to the U.S. False Statements Law (42 U.S.C.
Section&nbsp;1320a- 7b(a)), 18 U.S.C. Sections 286, 287, 1035, 1347, 1349 and the health care fraud criminal provisions under the U.S.
Health Insurance Portability and Accountability Act of 1996 (&ldquo;<B>HIPAA</B>&rdquo;) (42 U.S.C. Section&nbsp;1320d et seq.), the
exclusion laws (42 U.S.C. Section&nbsp;1320a-7), the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h), the statutes, regulations
and directives of applicable government funded or sponsored healthcare programs, including the collection and reporting requirements,
and the processing of any applicable rebate, chargeback or adjustment, under applicable rules&nbsp;and regulations relating to the Medicaid
Drug Rebate Program (42 U.S.C. &sect; 1396r-8) and any state supplemental rebate program, Medicare average sales price reporting (42
U.S.C. &sect; 1395w-3a), the Public Health Service Act (42 U.S.C. &sect; 256b), the VA Federal Supply Schedule (38 U.S.C. &sect; 8126)
or under any state pharmaceutical assistance program or U.S. Department of Veterans Affairs agreement, and any successor government programs,
and the regulations promulgated pursuant to such statutes; (iii)&nbsp;to the extent applicable, the Standards for Privacy of Individually
Identifiable Health Information, the Security Standards, and the Standards for Electronic Transactions and Code Sets promulgated under
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), and
the regulations promulgated thereunder and any state or non-U.S. counterpart thereof or other law or regulation the purpose of which
is to protect the privacy of individuals or prescribers; (iv)&nbsp;the Patient Protection and Affordable Care Act of 2010, as amended
by the Health Care and Education Reconciliation Act of 2010, the regulations promulgated thereunder; (v)&nbsp;the U.S. Controlled Substances
Act (21 U.S.C. Section&nbsp;801 et seq.); (vi)&nbsp;licensure, quality, safety and accreditation requirements under applicable federal,
state, local or foreign laws or regulatory bodies; and (vii)&nbsp;all other local, state, federal, national, supranational and foreign
laws, relating to the regulation of the Company or its subsidiaries. Neither the Company nor any of its subsidiaries has received any
FDA Form&nbsp;483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice of any
claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other material action from any court or arbitrator
or governmental or regulatory authority or third party alleging that any product, operation, or activity is in violation of any Health
Care Laws nor is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened.
The Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments were in all material respects timely, complete, accurate
and not misleading on the date filed (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its
subsidiaries is a party to any corporate integrity agreements, deferred or non- prosecution agreements, monitoring agreements, consent
decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither
the Company, any of its subsidiaries nor any of their respective employees, officers, directors or, to the Company&rsquo;s knowledge,
agents, has been excluded, suspended or debarred from participation in any U.S. federal health care program (as defined in 42 USC &sect;
1320a-7b(f)) or human clinical research or is subject to a governmental inquiry, investigation, proceeding, or other similar action that
could reasonably be expected to result in debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(qq)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Safety
Notices.</I></B> There have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings, safety
alerts or other notice of action relating to an alleged lack of safety, efficacy or regulatory compliance of the products manufactured,
distributed, or to the Company&rsquo;s knowledge, promoted by the Company (collectively, &ldquo;<B>Safety Notices</B>&rdquo;). To the
Company&rsquo;s knowledge, there are no material complaints with respect to the products manufactured, distributed or promoted by the
Company that are currently unresolved. To the Company&rsquo;s knowledge, there are no facts that would be reasonably likely to result
in (A)&nbsp;a material Safety Notice with respect to the products manufactured, distributed or promoted by the Company; (B)&nbsp;a material
change in labeling of any of the products manufactured, distributed or promoted by the Company; or (C)&nbsp;a termination or suspension
of marketing, distribution or testing of any of the products manufactured, distributed or promoted by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(rr)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>No
Rights to Purchase Preferred Stock</I></B>. The issuance and sale of the Shares as contemplated hereby will not cause any holder of any
shares of capital stock, securities convertible into or exchangeable or exercisable for capital stock or options, warrants or other rights
to purchase capital stock or any other securities of the Company to have any right to acquire any shares of preferred stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ss)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>No
Contract Terminations. </I></B>Except as disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus, (i)&nbsp;neither
the Company nor any of its subsidiaries has sent or received any communication regarding termination of, or intent not to renew, any
of the contracts or agreements referred to or described in any preliminary prospectus, the Prospectus or any free writing prospectus,
or referred to or described in, or filed as an exhibit to, the Registration Statement, and (ii)&nbsp;no such termination or non-renewal
has been threatened by the Company or any of its subsidiaries or, to the Company&rsquo;s knowledge, any other party to any such contract
or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(tt)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Cybersecurity</I></B>.
The Company and its subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, data and databases (collectively, &ldquo;<B>IT Systems and Data</B>&rdquo;) are adequate for, and operate and
perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as
currently conducted, and to the Company&rsquo;s knowledge, are free and clear of all material bugs, errors, defects, Trojan horses, time
bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained appropriate physical, technical
and administrative controls, policies, procedures, and safeguards to maintain and protect the integrity, continuous operation, redundancy
and security of the IT Systems and Data, reasonably consistent with industry standards and practices, or as required by applicable regulatory
standards. There have been no breaches, violations, outages or unauthorized uses of or accesses to the IT Systems and Data, and neither
the Company nor its subsidiaries have been notified of any event or condition that could result in, or has resulted in same, except for
those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal
review or investigations relating to the same. The Company and its subsidiaries have implemented and maintained backup and disaster recovery
technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(uu)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Compliance
with Data Privacy Laws</I></B>. The Company and its subsidiaries are, and at all prior times have been, in material compliance with all
applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations of any court or arbitrator or governmental or regulatory
authority, policies, applicable industry standards, and contractual obligations relating to the privacy and security of IT Systems and
Data, including the collection, storage, transfer (including, without limitation, any transfer across national borders), processing and/or
use of data and, and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification (collectively,
the &ldquo;<B>Data Protection Requirements</B>&rdquo;). To ensure compliance with the Data Protection Requirements, the Company and its
subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects
with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and
analysis of data (the &ldquo;<B>Policies</B>&rdquo;). The Company and its subsidiaries have at all times made all disclosures to users
or customers required by applicable Data Protection Requirements, and none of such disclosures made or contained in any Policy have,
to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules&nbsp;or requirements in
any material respect. Neither the Company nor any subsidiary: (i)&nbsp;has received notice of any actual or potential liability under
or relating to, or actual or potential violation of, any of the Data Protection Requirements, or has knowledge of any event or condition
that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part,
any investigation, remediation, or other corrective action pursuant to any Data Protection Requirement; or (iii)&nbsp;is a party to any
order, decree, or agreement that imposes any obligation or liability under any Data Protection Requirement. The execution, delivery and
performance of this Agreement or any other agreement referred to in this Agreement will not result in a breach of any Data Protection
Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Sarbanes-Oxley
Act</I></B>. Each of the Company and the Company&rsquo;s directors and officers, in their capacities as such, is in compliance, in all
material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any certificate signed by any
officer of the Company and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase
and sale, of the Offered Shares shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered
thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company has a reasonable
basis for making each of the representations set forth in this Section&nbsp;1. The Company acknowledges that the Underwriters and, for
purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the Underwriters, will
rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Purchase,
Sale and Delivery of the Offered Shares</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>The
Offered Shares</I>. </B>Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters an aggregate
of 3,491,620 Offered Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but
subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company the respective
number of Offered Shares set forth opposite their names on <U>Schedule A</U>. The purchase price per Offered Share to be paid by the
several Underwriters to the Company shall be $6.7304 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>The
Closing Date</I>. </B>Delivery of the book-entry positions for the Offered Shares to be purchased by the Underwriters and payment therefor
shall be made at the offices of Latham&nbsp;&amp; Watkins LLP (or such other place as may be agreed to by the Company and the Representative)
at 9:00 a.m.&nbsp;New York City time, on December&nbsp;14, 2023, or such other time and date not later than 1:30 p.m.&nbsp;New York City
time, on December&nbsp;14, 2023 as the Representative shall designate by notice to the Company (the time and date of such closing are
called the &ldquo;<B>Closing Date</B>&rdquo;). The Company hereby acknowledges that circumstances under which the Representative may
provide notice to postpone the Closing Date as originally scheduled include, but are not limited to, any determination by the Company
or the Representative to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the
provisions of Section&nbsp;11 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>[Reserved].</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Public
Offering of the Offered Shares</I>. </B>The Representative hereby advises the Company that the Underwriters intend to offer for sale
to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their
respective portions of the Offered Shares as soon after this Agreement has been executed and the Registration Statement has been declared
effective as the Representative, in its sole judgment, have determined is advisable and practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Payment
for the Offered Shares</I>. </B>Payment for the Offered Shares shall be made at the Closing Date by wire transfer of immediately available
funds to the order of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">It is understood that the Representative
has been authorized, for their own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make
payment of the purchase price for, the Offered Shares. BofA, individually and not as the Representative of the Underwriters, may (but
shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been received
by the Representative by the Closing Date, for the account of such Underwriter, but any such payment shall not relieve such Underwriter
from any of its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Delivery
of the Offered Shares</I>. </B>The Company shall deliver, or cause to be delivered to the Representative for the accounts of the several
Underwriters the book-entry positions for the Offered Shares at the Closing Date, against release of a wire transfer of immediately available
funds for the amount of the purchase price therefor. The book-entry positions for the Offered Shares shall be registered in such names
and denominations as the Representative shall have requested at least two full business days prior to the Closing Date and shall be made
available for inspection on the business day preceding the Closing Date at a location in New York City as the Representative may designate.
Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations
of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Additional
Covenants</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Delivery
of Registration Statement, Time of Sale Prospectus and Prospectus. </I></B>The Company shall furnish to you in New York City, without
charge, prior to 10:00 a.m.&nbsp;New York City time on the business day next succeeding the date of this Agreement and during the period
when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance
with Rule&nbsp;172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many copies of the
Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Representative&rsquo;s
Review of Proposed Amendments and Supplements. </I></B>During the period when a prospectus relating to the Offered Shares is required
by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar
rule), the Company (i)&nbsp;will furnish to the Representative for review, a reasonable period of time prior to the proposed time of
filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will
not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under
the Exchange Act) without the Representative&rsquo;s prior written consent. Prior to amending or supplementing any preliminary prospectus,
the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report filed under
the Exchange Act), the Company shall furnish to the Representative for review, a reasonable amount of time prior to the time of filing
or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use
any such proposed amendment or supplement without the Representative&rsquo;s prior written consent. The Company shall file with the Commission
within the applicable period specified in Rule&nbsp;424(b)&nbsp;under the Securities Act any prospectus required to be filed pursuant
to such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Free
Writing Prospectuses. </I></B>The Company shall furnish to the Representative for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or
on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus
or any amendment or supplement thereto without the Representative&rsquo;s prior written consent. The Company shall furnish to each Underwriter,
without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such
Underwriter may reasonably request. If at any time when a prospectus is required by the Securities Act to be delivered (whether physically
or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares
(but in any event if at any time through and including the Closing Date) there occurred or occurs an event or development as a result
of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict
with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted
or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing
at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such
conflict so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of
a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
prevailing at such time, not misleading, as the case may be; <I>provided, however</I>, that prior to amending or supplementing any such
free writing prospectus, the Company shall furnish to the Representative for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file,
use or refer to any such amended or supplemented free writing prospectus without the Representative&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Filing
of Underwriter Free Writing Prospectuses. </I></B>The Company shall not take any action that would result in an Underwriter or the Company
being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing prospectus prepared
by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Amendments
and Supplements to Time of Sale Prospectus. </I></B>If the Time of Sale Prospectus is being used to solicit offers to buy the Offered
Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as
a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include
an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result
of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the opinion of
counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company
shall (subject to Section&nbsp;3(b)&nbsp;and Section&nbsp;3(c)&nbsp;hereof) promptly prepare, file with the Commission and furnish, at
its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus
so that the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered
to a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict
with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will
comply with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Certain
Notifications and Required Actions</I>. </B>After the date of this Agreement, the Company shall promptly advise the Representative in
writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;the
time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary
prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the time and date that any post-effective
amendment to the Registration Statement becomes effective; (iv)&nbsp;the issuance by the Commission of any stop order suspending the
effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary
prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus,
the Time of Sale Prospectus, any free writing prospectus or the Prospectus or the initiation or, to the Company&rsquo;s knowledge, threatening
of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; and (v)&nbsp;of any proceedings to remove, suspend
or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or
designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter
any such stop order at any time, the Company will use its reasonable efforts to obtain the lifting of such order at the earliest possible
moment. Additionally, the Company agrees that it shall comply with all applicable provisions of Rule&nbsp;424(b), Rule&nbsp;433 and Rule&nbsp;430B
under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule&nbsp;424(b)&nbsp;or
Rule&nbsp;433 were received in a timely manner by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Amendments
and Supplements to the Prospectus and Other Securities Act Matters. </I></B>If any event shall occur or condition exist as a result of
which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) to a purchaser,
not misleading, or if in the opinion of the Representative or counsel for the Underwriters it is otherwise necessary to amend or supplement
the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(b)&nbsp;and Section&nbsp;3(c)&nbsp;hereof)
to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments
or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
when the Prospectus is delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar
rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither
the Representative&rsquo;s consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&rsquo;s
obligations under Section&nbsp;3(b)&nbsp;or Section&nbsp;3(c)&nbsp;of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Blue
Sky Compliance</I>. </B>The Company shall cooperate with the Representative and counsel for the Underwriters to qualify or register the
Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial
securities laws of those jurisdictions designated by the Representative, shall comply with such laws and shall continue such qualifications,
registrations and exemptions in effect so long as required for the distribution of the Offered Shares. Notwithstanding the foregoing,
the Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service
of process in any such jurisdiction where it is not presently qualified. The Company will advise the Representative promptly of the suspension
of the qualification or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction
or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification,
registration or exemption, the Company shall use its reasonable efforts to obtain the withdrawal thereof at the earliest possible moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Use
of Proceeds</I>. </B>The Company shall apply the net proceeds from the sale of the Offered Shares sold by it in the manner described
under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Transfer
Agent</I>. </B>The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Earnings
Statement</I>. </B>The Company will make generally available to its security holders and to the Representative as soon as practicable
an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter
of the Company commencing after the date of this Agreement that will satisfy the provisions of Section&nbsp;11(a)&nbsp;of the Securities
Act and the rules&nbsp;and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Continued
Compliance with Securities Laws</I>. </B>The Company will comply with the Securities Act and the Exchange Act so as to permit the completion
of the distribution of the Offered Shares as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus
and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating
to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172
under the Securities Act or any similar rule), file on a timely basis with the Commission and Nasdaq all reports and documents required
to be filed under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Listing</I>.
</B>The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Company
to Provide Copy of the Prospectus in Form&nbsp;That May&nbsp;be Downloaded from the Internet</I>. </B>If requested by the Representative,
the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement,
to the Representative an &ldquo;<B>electronic Prospectus</B>&rdquo; to be used by the Underwriters in connection with the offering and
sale of the Offered Shares. As used herein, the term &ldquo;<B>electronic Prospectus</B>&rdquo; means a form of Time of Sale Prospectus,
and any amendment or supplement thereto, that meets each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;it shall be encoded in an electronic format, satisfactory to the Representative, that may be
transmitted electronically by the Representative and the other Underwriters to offerees and purchasers of the Offered Shares; (ii)&nbsp;it
shall disclose the same information as the paper Time of Sale Prospectus, except to the extent that graphic and image material cannot
be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic Prospectus with a fair
and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible
into a paper format or an electronic format, satisfactory to the Representative, that will allow investors to store and have continuously
ready access to the Time of Sale Prospectus at any future time, without charge to investors (other than any fee charged for subscription
to the Internet as a whole and for on-line time). The Company hereby confirms that it has included or will include in the Prospectus
filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it was declared effective an undertaking
that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly,
without charge, a paper copy of the Time of Sale Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Agreement
Not to Offer or Sell Additional Shares</I>. </B>During the period commencing on and including the date hereof and continuing through
and including the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to herein
as the &ldquo;<B>Lock-up Period</B>&rdquo;), the Company will not, without the prior written consent of the Representative (which consent
may be withheld in their sole discretion), directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any Shares
or Related Securities (as defined below); (ii)&nbsp;effect any short sale, or establish or increase any &ldquo;put equivalent position&rdquo;
(as defined in Rule&nbsp;16a-1(h)&nbsp;under the Exchange Act) or liquidate or decrease any &ldquo;call equivalent position&rdquo; (as
defined in Rule&nbsp;16a-1(b)&nbsp;under the Exchange Act) of any Shares or Related Securities; (iii)&nbsp;pledge, lend, hypothecate
or grant any security interest in any Shares or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Shares or Related
Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic
risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in
cash or otherwise; (vi)&nbsp;announce the offering of any Shares or Related Securities; (vii)&nbsp;file any registration statement under
the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered
Shares); or (viii)&nbsp;publicly announce the intention to do any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect
the transactions contemplated hereby, (B)&nbsp;issue Shares or options to purchase Shares, or issue Shares upon exercise of options,
pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, (C)&nbsp;issue Shares upon the exercise of outstanding warrants described in the Registration Statement,
the Time of Sale Prospectus and the Prospectus and (D)&nbsp;file a new shelf registration statement on Form&nbsp;S-3 with the Commission
prior to the Renewal Deadline (as defined in Section&nbsp;3(w)&nbsp;below). For purposes of the foregoing, &ldquo;<B>Related Securities</B>&rdquo;
shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible
into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Future
Reports to the Representative. </I></B>During the period of five years hereafter, the Company will furnish to the Representative, c/o
BofA Securities,&nbsp;Inc., One Bryant Park, New York, New York 10036, Attention: Syndicate Department (email: dg.ecm_execution_services@bofa.com),
with a copy to ECM Legal (email: dg.ecm_legal@bofa.com): (i)&nbsp;as soon as practicable after the end of each fiscal year, copies of
the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income,
stockholders&rsquo; equity and cash flows for the year then ended and the opinion thereon of the Company&rsquo;s independent public or
certified public accountants; (ii)&nbsp;as soon as practicable after the filing or furnishing thereof, copies of each proxy statement,
Annual Report on Form&nbsp;10-K, Quarterly Report on Form&nbsp;10-Q, Current Report on Form&nbsp;8-K or other report filed or furnished
by the Company with the Commission or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication
of the Company furnished or made available generally to holders of its capital stock; <I>provided, however, </I>that the requirements
of this Section&nbsp;3(q)&nbsp;shall be satisfied to the extent that such reports, statement, communications, financial statements or
other documents are available on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Investment
Limitation</I>. </B>The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Shares
in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>No
Stabilization or Manipulation; Compliance with Regulation M</I>. </B>The Company will not take, and will ensure that no affiliate of
the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation
of the price of the Shares or any reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered
Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation
M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Enforce
Lock-Up Agreements</I>. </B>During the Lock-up Period, the Company will enforce all agreements between the Company and any of its security
holders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related Securities or any of the
other actions restricted or prohibited under the terms of the form of Lock-up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Company
to Provide Interim Financial Statements</I>. </B>Prior to the Closing Date, the Company will furnish the Underwriters, as soon as they
have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period
subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>[Reserved].</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Emerging
Growth Company Status</I></B>. The Company will promptly notify the Representative if the Company ceases to be an Emerging Growth Company
at any time prior to the later of (i)&nbsp;the time when a prospectus relating to the Offered Shares is not required by the Securities
Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) and (ii)&nbsp;the
expiration of the Lock-Up Period (as defined herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Representative, on behalf
of the several Underwriters, may, in its sole discretion, waive in writing the performance by the Company of any one or more of the foregoing
covenants or extend the time for their performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Shelf
Renewal</I></B>. If immediately prior to the third anniversary (the &ldquo;<B>Renewal Deadline</B>&rdquo;) of the initial effective date
of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline,
file, if it has not already done so and is eligible to do so, a new automatic shelf registration statement relating to the Shares, in
a form satisfactory to the Representative. If the Company is not eligible to file an automatic shelf registration statement, the Company
will, prior to the Renewal Deadline, if it has not already done so, file a new shelf registration statement relating to the Shares, in
a form satisfactory to the Representative, and will use its best efforts to cause such registration statement to be declared effective
within 180 days after the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and
sale of the Shares to continue as contemplated in the expired registration statement relating to the Shares. References herein to the
Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment
of Expenses. </B></FONT>The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations
hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to
the issuance and delivery of the Offered Shares (including all printing and engraving costs), (ii)&nbsp;all fees and expenses of the
registrar and transfer agent of the Shares, (iii)&nbsp;all stamp or other issuance or transfer taxes or duties, other similar fees or
charges which may be imposed by any governmental or regulatory authority in connection with the execution and delivery of this Agreement
or the issuance and sale of the Offered Shares to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&rsquo;s counsel, independent
public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation,
printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents
and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of,
used by, or referred to by the Company, and each preliminary prospectus, any Marketing Materials, and all amendments and supplements
thereto, and this Agreement, (vi)&nbsp;all filing fees, attorneys&rsquo; fees and expenses incurred by the Company or the Underwriters
in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the
Offered Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested
by the Representative, preparing and printing a &ldquo;Blue Sky Survey&rdquo; or memorandum and a &ldquo;Canadian wrapper&rdquo;, and
any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii)&nbsp;the costs, fees and
expenses incurred by the Underwriters in connection with determining their compliance with the rules&nbsp;and regulations of FINRA related
to the Underwriters&rsquo; participation in the offering and distribution of the Offered Shares, including any related filing fees and
the legal fees of, and disbursements by, counsel to the Underwriters, (viii)&nbsp;the costs and expenses of the Company relating to investor
presentations on any &ldquo;road show&rdquo; undertaken in connection with the offering of the Offered Shares, including, without limitation,
expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road
show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior
approval of the Company, travel and lodging expenses of the Representative, employees and officers of the Company and any such consultants,
and one half of the cost of any aircraft chartered in connection with the road show, with the other half being paid by the Underwriters,
(ix)&nbsp;the fees and expenses associated with listing the Offered Shares on Nasdaq and (x)&nbsp;all other fees, costs and expenses
of the nature referred to in Item 14 of Part&nbsp;II of the Registration Statement, <I>provided, however, </I>that the Company shall
not be responsible for any costs, fees and expenses of the Underwriters related to clauses (vi)&nbsp;or (vii)&nbsp;in excess of $25,000
in the aggregate. Except as provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters
shall pay their own expenses, including the fees and disbursements of their counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Covenant
of the Underwriters. </B></FONT>Each Underwriter severally and not jointly covenants with the Company not to take any action that would
result in the Company being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing
prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the
Company under Rule&nbsp;433(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions
of the Obligations of the Underwriters. </B></FONT>The respective obligations of the several Underwriters hereunder to purchase and pay
for the Offered Shares as provided herein on the Closing Date and shall be subject to the accuracy of the representations and warranties
on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the Closing Date as though then made and
to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Comfort
Letter</I>. </B>On the date hereof, the Representative shall have received from PricewaterhouseCoopers LLP, independent registered public
accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the
Representative, containing statements and information of the type ordinarily included in accountant&rsquo;s &ldquo;comfort letters&rdquo;
to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the
audited and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale
Prospectus, and each free writing prospectus, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Compliance
with Registration Requirements; No Stop Order; No Objection from FINRA.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company shall have filed the Prospectus with the Commission (including the information previously omitted from the Registration Statement
pursuant to Rule&nbsp;430B under the Securities Act) in the manner and within the time period required by Rule&nbsp;424(b)&nbsp;under
the Securities Act; or the Company shall have filed a post-effective amendment to the Registration Statement containing the information
previously omitted from the Registration Statement pursuant to Rule&nbsp;430B, and such posteffective amendment shall have become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall
be in effect, and no proceedings for such purpose or pursuant to Section&nbsp;8A of the Securities Act shall have been instituted or
threatened by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;FINRA
shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>No
Material Adverse Change or Ratings Agency Change</I>. </B>For the period from and after the date of this Agreement and through and including
the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the judgment of the Representative there shall not have occurred any Material Adverse Change; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;there
shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review
for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company
by any &ldquo;nationally recognized statistical rating organization&rdquo; as that term is used in Rule&nbsp;15c3-1(c)(2)(vi)(F)&nbsp;under
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Opinion
of Counsel for the Company</I>. </B>On the Closing Date, the Representative shall have received the opinion of DLA Piper LLP (US), counsel
for the Company, in form and substance satisfactory to the Underwriters, dated as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Opinion
of Morgan, Lewis&nbsp;&amp; Bockius LLP. </I></B>On the Closing Date, the Representative shall have received the opinion of Morgan, Lewis&nbsp;&amp;
Bockius LLP, counsel for the Company with respect to intellectual property matters, in form and substance satisfactory to the Underwriters,
dated as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Opinion
of Counsel for the Underwriters</I>. </B>On the Closing Date, the Representative shall have received the opinion of Latham&nbsp;&amp;
Watkins LLP, counsel for the Underwriters in connection with the offer and sale of the Offered Shares, in form and substance satisfactory
to the Underwriters, dated as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Officers&rsquo;
Certificate</I>. </B>On the Closing Date, the Representative shall have received a certificate executed by the Chief Executive Officer
or President of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii)&nbsp;hereof
and further to the effect that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse
Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
representations, warranties and covenants of the Company set forth in Section&nbsp;1 of this Agreement are true and correct with the
same force and effect as though expressly made on and as of such date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder
at or prior to such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Bring-down
Comfort Letter</I>. </B>On the Closing Date, the Representative shall have received from PricewaterhouseCoopers LLP, independent registered
public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representative, which letter
shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a)&nbsp;of this Agreement, except
that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the
Closing Date; and (ii)&nbsp;cover certain financial information contained in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Lock-Up
Agreements. </I></B>On or prior to the date hereof, the Company shall have furnished to the Representative an agreement substantially
in the form of <U>Exhibit&nbsp;A</U> hereto from each of the persons listed on <U>Exhibit&nbsp;B</U> hereto, and each such agreement
shall be in full force and effect on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>CFO
Certificate</I></B>. On the date hereof and the Closing Date, the Representative shall have received a certificate executed by the Chief
Financial Officer of the Company, on behalf of the Company and not in his individual capacity dated as of such date, in form and substance
satisfactory to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Rule&nbsp;462(b)&nbsp;Registration
Statement</I>. </B>In the event that a Rule&nbsp;462(b)&nbsp;Registration Statement is filed in connection with the offering contemplated
by this Agreement, such Rule&nbsp;462(b)&nbsp;Registration Statement shall have been filed with the Commission on the date of this Agreement
and shall have become effective automatically upon such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Approval
of Listing</I></B>. At the Closing Date, the Offered Shares shall have been approved for listing on Nasdaq, subject only to official
notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Additional
Documents</I></B>. On or before the Closing Date, the Representative and counsel for the Underwriters shall have received such information,
documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered
Shares as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction
of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and
sale of the Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall
be satisfactory in form and substance to the Representative and counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any condition specified
in this Section&nbsp;6 is not satisfied when and as required to be satisfied (unless waived by the Representative), this Agreement may
be terminated by the Representative by notice from the Representative to the Company at any time on or prior to the Closing Date, which
termination shall be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9
and Section&nbsp;10 of this Agreement shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Reimbursement
of Underwriters&rsquo; Expenses</B></FONT>. If this Agreement is terminated by the Representative pursuant to Section&nbsp;6, Section&nbsp;11
or Section&nbsp;12 of this Agreement, or if the sale to the Underwriters of the Offered Shares on the Closing Date is not consummated
because of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision
hereof, the Company agrees to reimburse the Representative and the other Underwriters, severally, upon demand for all reasonable and
documented out-of-pocket expenses that shall have been reasonably incurred by the Representative and the Underwriters in connection with
the proposed purchase and the offering and sale of the Offered Shares, including, but not limited to, fees and disbursements of counsel,
printing expenses, travel expenses, postage, facsimile and telephone charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Effectiveness
of this Agreement</B></FONT>. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indemnification</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Indemnification
of the Underwriters</I>. </B>The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors, officers,
employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange
Act against any loss, claim, damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer,
employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory
law or regulation, or the laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold or at common law
or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company or is
effected pursuant to Section&nbsp;9(d)&nbsp;below) insofar as such loss, claim, damage, liability or expense (or actions in respect thereof
as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue
statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the
Company has used, referred to or filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;of the Securities Act, any Marketing
Material or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a
material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading;
or (iii)&nbsp;any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any
manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage,
liability or action arising out of or based upon any matter covered by clause (i)&nbsp;or (ii)&nbsp;above; and to reimburse each Underwriter
and each such affiliate, director, officer, employee, agent and controlling person for any and all reasonable expenses (including the
reasonable fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer,
employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim,
damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim,
damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue
statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished
to the Company by the Representative in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time
of Sale Prospectus, any such free writing prospectus, any Marketing Material or the Prospectus (or any amendment or supplement thereto),
it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b)&nbsp;below.
The indemnity agreement set forth in this Section&nbsp;9(a)&nbsp;shall be in addition to any liabilities that the Company may otherwise
have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Indemnification
of the Company, its Directors and Officers. </I></B>Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless
the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls
the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred,
to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange
Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation,
if such settlement is effected with the written consent of such Underwriter or is effected pursuant to Section&nbsp;9(d)&nbsp;below),
insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based
upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment
thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary
prospectus, the Time of Sale Prospectus, any free writing prospectus, that the Company has used, referred to or filed, or is required
to file, pursuant to Rule&nbsp;433 of the Securities Act, any Marketing Material or the Prospectus (or any such amendment or supplement)
or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances
under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged
untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale
Prospectus, such free writing prospectus, such Marketing Material or the Prospectus (or any such amendment or supplement), in reliance
upon and in conformity with information relating to such Underwriter furnished to the Company by the Representative in writing expressly
for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all reasonable expenses
(including the reasonable fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer
or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability,
expense or action. The Company hereby acknowledges that the only information that the Representative has furnished to the Company expressly
for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the
Company has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;of the Securities Act, any Marketing Material or the Prospectus
(or any amendment or supplement to the foregoing) are the statements set forth in the first paragraph under the heading &ldquo;Underwriting&mdash;Commissions
and Discounts,&rdquo; the statements set forth in the second, third and fourth paragraphs under the heading &ldquo;Underwriting&mdash;Price
Stabilization, Short Positions&rdquo; and the statements set forth under the heading &ldquo;Underwriting&mdash;Electronic Distribution,&rdquo;
under the caption &ldquo;Underwriting&rdquo; in any preliminary prospectus supplement and the Final Prospectus Supplement. The indemnity
agreement set forth in this Section&nbsp;9(b)&nbsp;shall be in addition to any liabilities that each Underwriter may otherwise have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Notifications
and Other Indemnification Procedures</I>. </B>Promptly after receipt by an indemnified party under this Section&nbsp;9 of notice of the
commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under
this Section&nbsp;9, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying
party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying
party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from
any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against any
indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will
be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified,
by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume
the defense thereof with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants
in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded
that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any
such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional
to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume
such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt
of notice from the indemnifying party to such indemnified party of such indemnifying party&rsquo;s election so to assume the defense
of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party
under this Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense
thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence
(it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel
(together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any
local counsel) for the indemnified parties shall be selected by the Representative (in the case of counsel for the indemnified parties
referred to in Section&nbsp;9(a)&nbsp;above) or by the Company (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b)&nbsp;above))
or (ii)&nbsp;the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the
indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized
in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees
and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Settlements</I>.
</B>The indemnifying party under this Section&nbsp;9 shall not be liable for any settlement of any proceeding effected without its written
consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify
the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding
the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party
for fees and expenses of counsel as contemplated by Section&nbsp;9(c)&nbsp;hereof, the indemnifying party shall be liable for any settlement
of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by
such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party
in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent
of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action,
suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought
hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified
party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of
fault or culpability or a failure to act by or on behalf of such indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Contribution</B></FONT>.
If the indemnification provided for in Section&nbsp;9 of this Agreement is for any reason held to be unavailable to or otherwise insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any
losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative
benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant
to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion
as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the Company,
on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses,
claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the
Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Shares pursuant to
this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Shares
pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth on the front cover page&nbsp;of the Prospectus, bear to the aggregate initial
public offering price of the Offered Shares as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters,
on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a
material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand,
or the Underwriters, on the other hand, and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount paid or payable
by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject
to the limitations set forth in Section&nbsp;9(c)&nbsp;of this Agreement, any legal or other fees or expenses reasonably incurred by
such party in connection with investigating or defending any action or claim. The provisions set forth in Section&nbsp;9(c)&nbsp;of this
Agreement with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10;
<I>provided, however, </I>that no additional notice shall be required with respect to any action for which notice has been given under
Section&nbsp;9(c)&nbsp;of this Agreement for purposes of indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and the Underwriters
agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were determined by pro rata allocation
(even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account
of the equitable considerations referred to in this Section&nbsp;10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the provisions
of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions
received by such Underwriter in connection with the Offered Shares underwritten by it and distributed to the public. No person guilty
of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&rsquo; obligations to contribute pursuant to
this Section&nbsp;10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their
respective names on <U>Schedule A</U>. For purposes of this Section&nbsp;10, each affiliate, director, officer, employee and agent of
an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall
have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the
Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act
shall have the same rights to contribution as the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Default
of One or More of the Several Underwriters</B></FONT><I>. </I>If, on the Closing Date any one or more of the several Underwriters shall
fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number of
Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the
aggregate number of the Offered Shares to be purchased on such date, the Representative may make arrangements satisfactory to the Company
for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by
such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Offered Shares
set forth opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Offered Shares set forth opposite the
names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representative with the consent
of the non-defaulting Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters agreed but failed
or refused to purchase on such date. If, on the Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered
Shares and the aggregate number of Offered Shares with respect to which such default occurs exceeds 10% of the aggregate number of Offered
Shares to be purchased on such date, and arrangements satisfactory to the Representative and the Company for the purchase of such Offered
Shares are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party
except that the provisions of Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 of this Agreement shall at all times
be effective and shall survive such termination. In any such case either the Representative or the Company shall have the right to postpone
the Closing Date, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement
and the Prospectus or any other documents or arrangements may be effected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Agreement,
the term &ldquo;<B>Underwriter</B>&rdquo; shall be deemed to include any person substituted for a defaulting Underwriter under this Section&nbsp;11.
Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of
such Underwriter under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Termination
of this Agreement</B></FONT><I>. </I>Prior to the purchase of the Offered Shares by the Underwriters on the Closing Date, this Agreement
may be terminated by the Representative by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any of the Company&rsquo;s
securities shall have been suspended or limited by the Commission or by Nasdaq, or trading in securities generally on either Nasdaq or
the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established
on any of such stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal or New York authorities;
(iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or
any change in the United States or international financial markets, or any substantial change or development involving a prospective
substantial change in United States&rsquo; or international political, financial or economic conditions, as in the judgment of the Representative
is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time
of Sale Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv)&nbsp;in the judgment of the Representative
there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood, earthquake,
accident or other calamity of such character as in the judgment of the Representative may interfere materially with the conduct of the
business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this
Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated
to reimburse the expenses of the Representative and the Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7 hereof or (b)&nbsp;any
Underwriter to the Company; <I>provided, however, </I>that the provisions of Section&nbsp;9 and Section&nbsp;10 hereof shall at all times
be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Advisory or Fiduciary Relationship. </B></FONT>The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the Offered
Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts
and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several Underwriters,
on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter
is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees
or any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company
with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised
or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering
contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates
may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters
have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has
consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Representations
and Indemnities to Survive Delivery</B></FONT><I>. </I>The respective indemnities, agreements, representations, warranties and other
statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain
in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their
partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding,
will survive delivery of and payment for the Offered Shares sold hereunder and any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notices</B></FONT>.
All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; vertical-align: top; width: 28%; text-align: left">If to
    the Representative:</TD><TD STYLE="text-align: left; width: 2%; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left">BofA Securities,&nbsp;Inc.
    <BR>One Bryant Park <BR>New York, New York 10036 <BR>Email: <U>dg.ecm_execution_services@bofa.com</U> <BR>Attention: Syndicate Department
    <BR>with a copy to: <BR>Email: dg.ecm_legal@bofa.com <BR>
    Attention: ECM Legal <BR></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; vertical-align: top; text-align: left">with a copy to:
    (which shall not constitute notice)</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Latham&nbsp;&amp; Watkins LLP <BR>1271
    Avenue of the Americas <BR>
    New York, New York 10020 <BR>
    Facsimile: (212) 751-4864 <BR>Attention: Nathan Ajiashvili and Alison Haggerty</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; vertical-align: top; text-align: left">If to the Company:</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Liquidia Corporation <BR>419 Davis Drive,
Suite&nbsp;100 <BR>
Morrisville, North Carolina 27560 <BR>&nbsp; <BR>Attention: Roger Jeffs</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; vertical-align: top; text-align: left">with a copy to:
    (which shall not constitute notice)</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">DLA Piper LLP (US) <BR>51 John F. Kennedy
    Parkway, Suite&nbsp;120 <BR>
    Short Hills, NJ 07078 <BR>Facsimile: (973) 520-2573 <BR>
    Attention: Andrew P. Gilbert</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any party hereto may change
the address for receipt of communications by giving written notice to the others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Successors</B></FONT><I>.
</I>This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute Underwriters pursuant
to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred
to in Section&nbsp;9 and Section&nbsp;10 hereof, and in each case their respective successors, and no other person will have any right
or obligation hereunder. The term &ldquo;<B>successors</B>&rdquo; shall not include any purchaser of the Offered Shares as such from
any of the Underwriters merely by reason of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Partial
Unenforceability</B></FONT>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect
the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement
is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor
changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Recognition
of the U.S. Special Resolution Regimes</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event that any Underwriter that is a Covered Entity (as defined below) becomes subject to a proceeding under a U.S. Special Resolution
Regime (as defined below), the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement,
will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate (as defined below) of such Underwriter becomes subject
to a proceeding under a U.S. Special Resolution Regime, Default Rights (as defined below) under this Agreement that may be exercised
against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. For purposes
of this Agreement, (A)&nbsp;&ldquo;<B>BHC Act Affiliate</B>&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and
shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k); (B)&nbsp;&ldquo;<B>Covered Entity</B>&rdquo; means any of the following:
(i)&nbsp;a &ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii)&nbsp;a
 &ldquo;covered bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii)&nbsp;a
 &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b); (C)&nbsp;&ldquo;<B>Default
Right</B>&rdquo; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81,
47.2 or 382.1, as applicable; and (D)&nbsp;&ldquo;<B>U.S. Special Resolution Regime</B>&rdquo; means each of (i)&nbsp;the Federal Deposit
Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection
Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Governing
Law Provisions</B></FONT><I>. </I>This Agreement and any claim, controversy or dispute arising hereunder or related hereto shall be governed
by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such
state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (&ldquo;<B>Related
Proceedings</B>&rdquo;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in
the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York
(collectively, the &ldquo;<B>Specified Courts</B>&rdquo;), and each party irrevocably submits to the exclusive jurisdiction (except for
proceedings instituted in regard to the enforcement of a judgment of any such court (a &ldquo;<B>Related Judgment</B>&rdquo;), as to
which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice
or document by mail to such party&rsquo;s address set forth above shall be effective service of process for any suit, action or other
proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit,
action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such
court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Waiver
of Jury Trial. </B></FONT>Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of
or relating to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Compliance
with USA Patriot Act. </B></FONT>In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into
law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective
clients, including the Company, which information may include the name and address of their respective clients, as well as other information
that will allow the Underwriters to properly identify their respective clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;22.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;General
Provisions. </B></FONT>This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written
or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement
may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto
and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto,
and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.
The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Electronic signatures complying
with the New York Electronic Signatures and Records Act (N.Y. State Tech. &sect;&sect; 301-309), as amended from time to time, or other
applicable law will be deemed original signatures for purposes of this Agreement. Transmission by telecopy, electronic mail or other
transmission method of an executed counterpart of this Agreement will constitute due and sufficient delivery of such counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the parties hereto
acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations regarding the provisions
hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10
hereof, and is fully informed regarding said provisions. Each of the parties hereto further acknowledges that the provisions of Section&nbsp;9
and Section&nbsp;10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and
its business in order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the
Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated
by the Securities Act and the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance
with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument,
along with all counterparts hereof, shall become a binding agreement in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIQUIDIA
    CORPORATION</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#8239;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Roger Jeffs&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Roger Jeffs</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Signature Page&nbsp;to
Underwriting Agreement</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 33; Options: NewSection; Value: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing Underwriting Agreement is hereby
confirmed and accepted by the Representative in New York, New York as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOFA
    SECURITIES,&nbsp;INC.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acting
    individually and as the Representative of the several Underwriters named in the attached <U>Schedule A</U>.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOFA
    SECURITIES,&nbsp;INC.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    John Bishai&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    John Bishai</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Managing Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>Signature Page&nbsp;to
Underwriting Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Schedule A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Underwriters</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Number
    of<BR>
    Offered Shares<BR>
    to be <BR>
    Purchased</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">BofA Securities,&nbsp;Inc.</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,793,296</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">BTIG, LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">698,324</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,491,620</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Schedule B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Free Writing Prospectuses Included in the
Time of Sale Prospectus</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Pricing Information Included in the Time
of Sale Prospectus</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 86%">Price per share to the public:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">7.16</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Number of shares being sold by the Company:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,491,620</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Schedule C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Marketing Materials</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form&nbsp;of Lock-Up Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representative of the several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o BofA Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Bryant Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">RE:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Liquidia
Corporation (the &ldquo;<B>Company</B>&rdquo;)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Ladies&nbsp;&amp; Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned is an owner of shares of common stock, par value $0.001
per share, of the Company (&ldquo;<B>Shares</B>&rdquo;) or of securities exchangeable or exercisable for Shares. The Company proposes
to conduct a public offering of Shares (the &ldquo;<B>Offering</B>&rdquo;) for which BofA Securities,&nbsp;Inc. (the &ldquo;<B>Representative</B>&rdquo;)
will act as the representative of the underwriters (the &ldquo;<B>Underwriters</B>&rdquo;) listed in Schedule A to the Underwriting Agreement
referred to below. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned. The undersigned
acknowledges that the Underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement
in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;)
and other underwriting arrangements with the Company with respect to the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Annex A sets forth definitions for capitalized
terms used in this letter agreement that are not defined in the body of this letter agreement. Those definitions are a part of this letter
agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In consideration of the foregoing, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during
the Lock-up Period, the undersigned will not (and will cause any Family Member not to), without the prior written consent of the Representative,
who may withhold their consent in their sole discretion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Sell or Offer to Sell
                                            any Shares or Related Securities currently or hereafter owned either of record or beneficially
                                            (as defined in Rule&nbsp;13d-3 under the Exchange Act) by the undersigned or such Family
                                            Member,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>enter into any Swap,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">make any demand for,
                                            or exercise any right with respect to, the registration under the Securities Act of the offer
                                            and sale of any Shares or Related Securities, or cause to be filed a registration statement,
                                            prospectus or prospectus supplement (or an amendment or supplement thereto) with respect
                                            to any such registration, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>publicly announce any
                                            intention to do any of the foregoing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing will not apply to the registration
of the offer and sale of the Shares, and the sale of the Shares to the Underwriters, in each case as contemplated by the Underwriting
Agreement. In addition, the foregoing restrictions shall not apply to (i)&nbsp;(A)&nbsp;the establishment or amendment of a trading plan
pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the transfer of Shares or Related Securities, <I>provided </I>that (x)&nbsp;no
public announcement or filing under the Exchange Act shall be voluntarily made in connection with such trading plan and, to the extent
any public announcement or filing under the Exchange Act is required by or on behalf of the undersigned or the Company regarding the
establishment or amendment of such trading plan, such announcement or filing shall include a statement to the effect that no transfer
of Shares may be made under such trading plan during the Lock-up Period, and (y)&nbsp;such trading plan shall not provide for or permit
any transfers, sales or other dispositions during the Lock-up Period, or (B)&nbsp;sales effected pursuant to a trading plan pursuant
to Rule&nbsp;10b5-1 under the Exchange Act that was in effect on the date hereof, <I>provided </I>that any filing required or voluntarily
made under the Exchange Act during the Lock-up Period shall note that such transaction was conducted pursuant to such preestablished
Rule&nbsp;10b5-1 trading plan; (ii)&nbsp;the transfer of Shares or Related Securities by gift, or by will or intestate succession to
a Family Member or to a trust whose beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member, or to
a charitable organization, <I>provided</I> that any filing required to be made under the Exchange Act discloses therein that such transfer
is a disposition by bona fide gift or otherwise a transfer for no value (and if the transferee is a person, trust or entity that would
report a corresponding acquisition of such securities on the undersigned's Form&nbsp;4, and such acquisition is entitled to be reported
on a Form&nbsp;5, such acquisition may be voluntarily reported on such Form&nbsp;4), (iii)&nbsp;transfers by operation of law, including
pursuant to a court or regulatory agency order, a qualified domestic relations order or in connection with a divorce settlement, (iv)&nbsp;transfers
as a distribution to limited partners, limited liability company members or stockholders of the undersigned, (v)&nbsp;transfers to a
corporation, partnership, limited liability company, investment fund or other entity that controls or is controlled by, or is under common
control with, the undersigned, or is wholly-owned by the undersigned, or, in the case of an investment fund, that is managed by, or is
under common management with, the undersigned (including, for the avoidance of doubt, a fund managed by the same manager or managing
member or general partner or management company or by an entity controlling, controlled by, or under common control with such manager
or managing member or general partner or management company as the undersigned or who shares a common investment advisor with the undersigned),
(vi)&nbsp;transfers of Shares or Related Securities pursuant to a bona fide third party tender offer, merger, consolidation or other
similar transaction made to all holders of Shares or Related Securities involving a Change of Control of the Company, <I>provided </I>that
in the event that the tender offer, merger, consolidation or other such transaction is not completed, the Shares or Related Securities
owned by the undersigned shall remain subject to the restrictions contained in this letter agreement and (vii)&nbsp;transfers of Shares
to the Company to cover the payment of taxes due upon or consideration required in connection with the vesting, conversion or exercise
of securities (including, in each case, by way of &ldquo;net&rdquo; or &ldquo;cashless&rdquo; exercise) or the sale of Shares necessary
to generate such amount of cash needed for the payment of withholding taxes due as a result of the vesting and settlement of restricted
stock units as disclosed in writing to the Representative prior to the date hereof and, in each case, issued under an equity incentive
plan or stock purchase plan of the Company existing on the date hereof and described in the prospectus for which the Offering relates,
<I>provided</I> that (x)&nbsp;any such Shares received upon such exercise, vesting or settlement shall be subject to the terms of this
letter agreement and (y)&nbsp;if the undersigned is required to make a filing under the Exchange Act, such filing shall include a footnote
describing the purpose of the transaction as described in this clause (vii); <I>provided, however</I>, that in any such case (except
with respect to clauses (i), (vi)&nbsp;and (vii)&nbsp;and as otherwise indicated above), it shall be a condition to such transfer that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">each transferee executes
                                            and delivers to the Representative an agreement in form and substance satisfactory to the
                                            Representative stating that such transferee is receiving and holding such Shares and/or Related
                                            Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer
                                            to Sell such Shares and/or Related Securities, engage in any Swap or engage in any other
                                            activities restricted under this letter agreement except in accordance with this letter agreement
                                            (as if such transferee had been an original signatory hereto),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">prior to the expiration
                                            of the Lock-up Period, no public disclosure or filing under the Exchange Act by any party
                                            to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily,
                                            reporting a reduction in beneficial ownership of Shares in connection with such transfer,
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any such transfers
                                            shall not involve a disposition for value.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Change of Control</B>&rdquo; shall mean
the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related
transactions, to a person or group of affiliated persons (other than an Underwriter pursuant to the Offering), of the Company&rsquo;s
voting securities if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting
securities of the Company (or the surviving entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With respect to the Offering only, the undersigned
waives any registration rights relating to registration under the Securities Act of the offer and sale of any Shares and/or any Related
Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned confirms that the undersigned
has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to or that might reasonably
be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
of the Shares. The undersigned will not, and will cause any Family Member not to take, directly or indirectly, any such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Whether or not the Offering occurs as currently
contemplated or at all depends on market conditions and other factors. The Offering will only be made pursuant to the Underwriting Agreement,
the terms of which are subject to negotiation between the Company and the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned acknowledges and agrees that the
Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned
with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to
the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representative may be required or choose
to provide certain Regulation Best Interest and Form&nbsp;CRS disclosures to you in connection with the Public Offering, the Representative
and the other Underwriters are not making a recommendation to you to enter into this letter agreement, and nothing set forth in such
disclosures is intended to suggest that the Representative or any Underwriter is making such a recommendation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that if, (i)&nbsp;the
Company notifies the Representative in writing that it does not intend to proceed with the Offering, (ii)&nbsp;the purchase of the Offered
Shares (as defined in the Underwriting Agreement) does not occur by December&nbsp;22, 2023, or (iii)&nbsp;the Underwriting Agreement
(other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the
Common Stock to be sold thereunder, then the undersigned shall be released from all obligations under this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned hereby represents and warrants
that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter agreement is irrevocable
and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This letter agreement and any claim, controversy
or dispute arising hereunder or related hereto shall be governed by, and construed in accordance with, the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page&nbsp;follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed
    Name of Person Signing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Indicate
    capacity of person signing if signing as custodian or trustee, or on behalf of an entity)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certain Defined Terms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Used in Lock-up Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">For purposes of the letter agreement to which this Annex
A is attached and of which it is made a part:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>Call Equivalent
                                            Position</B>&rdquo; shall have the meaning set forth in Rule&nbsp;16a-1(b)&nbsp;under the
                                            Exchange Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>Exchange Act</B>&rdquo;
                                            shall mean the Securities Exchange Act of 1934, as amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Family Member</B>&rdquo;
                                            shall mean the spouse of the undersigned, an immediate family member of the undersigned or
                                            an immediate family member of the undersigned&rsquo;s spouse, in each case living in the
                                            undersigned&rsquo;s household or whose principal residence is the undersigned&rsquo;s household
                                            (regardless of whether such spouse or family member may at the time be living elsewhere due
                                            to educational activities, health care treatment, military service, temporary internship
                                            or employment or otherwise). &ldquo;<B>Immediate family member</B>&rdquo; as used above shall
                                            have the meaning set forth in Rule&nbsp;16a-1(e)&nbsp;under the Exchange Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Lock-up Period</B>&rdquo;
                                            shall mean the period beginning on the date hereof and continuing through the close of trading
                                            on the date that is 90 days after the date of the Prospectus (as defined in the Underwriting
                                            Agreement).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>Put Equivalent Position</B>&rdquo;
                                            shall have the meaning set forth in Rule&nbsp;16a-1(h)&nbsp;under the Exchange Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Related
                                            Securities</B>&rdquo; shall mean any options or warrants or other rights to acquire Shares
                                            or any securities exchangeable or exercisable for or convertible into Shares, or to acquire
                                            other securities or rights ultimately exchangeable or exercisable for or convertible into
                                            Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>Securities Act</B>&rdquo;
                                            shall mean the Securities Act of 1933, as amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>&ldquo;<B>Sell or Offer to
                                            Sell</B>&rdquo; shall mean to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%">&ndash;</TD><TD>sell, offer to sell, contract to sell or lend,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%">&ndash;</TD><TD>effect any short sale or establish or increase a Put Equivalent Position
                                            or liquidate or decrease any Call Equivalent Position</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%">&ndash;</TD><TD>pledge, hypothecate or grant any security interest in, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%">&ndash;</TD><TD>in any other way transfer or dispose of,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">in each case whether effected directly or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">&ldquo;<B>Swap</B>&rdquo;
                                            shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole or
                                            in part, the economic risk of ownership of Shares or Related Securities, regardless of whether
                                            any such transaction is to be settled in securities, in cash or otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Capitalized terms not defined in this Annex A
shall have the meanings given to them in the body of this lock-up agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Officers</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Roger Jeffs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael Kaseta</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rajeev Saggar</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert A. Lippe</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Russell Schundler</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jason Adair</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott Moomaw</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Directors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stephen M. Bloch</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Damian deGoa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joanna Horobin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Johnson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Arthur Kirsch</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Manning</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Katie Rielly-Gauvin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Raman Singh</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Stockholders</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caligan Partners LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canaan VIII L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2332695d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 444.75pt">DLA Piper LLP (US)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 363pt">51 John F. Kennedy Parkway,
Suite&nbsp;120</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 405pt">Short Hills, New Jersey 07078</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 456pt">www.dlapiper.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 465pt">T: 973-520-2550</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 465.75pt">F: 973-520-2551</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 339.75pt">Attorneys Responsible for
Short Hills Office:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 474.75pt">Emilio Ragosa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;14, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Liquidia Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">419 Davis Drive, Suite&nbsp;100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morrisville, North Carolina 27560</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Re:</B>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Liquidia Corporation,
Registration Statement on Form&nbsp;S-3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have acted as counsel
to Liquidia Corporation, a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the sale by the Company of 3,491,620 shares
(&ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), <FONT STYLE="color: #212529">pursuant
to a registration statement on Form&nbsp;S-3 (File No.&nbsp;333-251394) (the &ldquo;Registration Statement&rdquo;), initially filed with
the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on December&nbsp;16, 2020 and declared effective by the SEC
on December&nbsp;23, 2020, and the prospectus contained therein, as supplemented by the prospectus supplement dated December&nbsp;12,
2023 (the &ldquo;Prospectus Supplement&rdquo;)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with this
opinion letter, we have examined the Registration Statement, the Prospectus Supplement and originals, or copies certified or otherwise
identified to our satisfaction, of the Certificate of Incorporation, as amended, and the Bylaws of the Company, and the minutes of meetings
of the stockholders and the Board of Directors, as provided to us by the Company, and such other documents, records and other instruments
as we have deemed appropriate for purposes of the opinion set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have assumed the genuineness
of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity
with the originals of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals
of all documents submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based upon the foregoing, we are of the opinion
that the Shares have been duly authorized and are validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The opinion expressed herein is limited to
the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We hereby consent to
the use of this opinion as Exhibit&nbsp;5.1 to the Company&rsquo;s Current Report on Form&nbsp;8-K filed with the SEC on December&nbsp;14,
2023 and its incorporation by reference into the Registration Statement and to the reference to us under the caption &ldquo;Legal Matters&rdquo;
in each of the base prospectus included in the Registration Statement and the Prospectus Supplement. In giving such consent, we do not
hereby admit that we are acting within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or
the rules&nbsp;or regulations of the U.S. Securities and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>/s/ DLA Piper LLP (US)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>tm2332695d2_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>COMMON STOCK PURCHASE
AGREEMENT</B> (this &ldquo;<B>Agreement</B>&rdquo;), dated as of December&nbsp;12, 2023, by and among Liquidia Corporation, a Delaware
corporation, with headquarters located at 419 Davis Drive, Suite&nbsp;100, Morrisville, NC 27560 (the &ldquo;<B>Company</B>&rdquo;) and
each of the investors listed on the Schedule of Buyers attached hereto (individually, a &ldquo;<B>Buyer</B>&rdquo; and collectively,
the &ldquo;<B>Buyers</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">A.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
each Buyer wishes to purchase from the Company at the Closing (as defined below), and the Company wishes to sell, upon the terms and
conditions stated in this Agreement, that aggregate number of shares of the Company&rsquo;s common stock, par value $0.001 per share
(the &ldquo;<B>Company Common Stock</B>&rdquo;) set forth opposite such Buyer&rsquo;s name in column (3)&nbsp;on the Schedule of Buyers
attached hereto (collectively, the &ldquo;<B>Common Shares</B>&rdquo;) for an aggregate purchase price as set forth opposite such Buyer&rsquo;s
name in column (4)&nbsp;on the Schedule of Buyers (provided that in no event shall the number of Common Shares issued and sold at the
Closing exceed 19.99% of the outstanding shares of Company Common Stock immediately prior to the date of this Agreement), and the Company
desires to sell the Common Shares to the Buyers, all on the terms and conditions set forth in this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">B.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
in reliance upon the representations made by each of the Buyers and the Company in this Agreement, the transactions contemplated by this
Agreement are such that the offer and sale of securities by the Company under this Agreement will be exempt from registration under applicable
United States securities laws as a result of the transaction being contemplated hereby being undertaken pursuant to Section&nbsp;4(a)(2)&nbsp;of
the Securities Act of 1933, as amended (the &ldquo;<B>1933 Act</B>&rdquo;) and Rule&nbsp;506 of Regulation D (&ldquo;<B>Regulation D</B>&rdquo;)
as promulgated by the U.S. Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the terms and conditions contained herein, and other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the Company and each Buyer hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">PURCHASE
AND SALE OF COMMON SHARES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purchase
of Common Shares</U>. Subject to the satisfaction (or waiver) of all of the conditions set forth in <U>Section&nbsp;5</U> and <U>Section&nbsp;6
</U>below, the Company, at the Closing, shall issue and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase
from the Company on the Closing Date (as defined below), the number of Common Shares as is set forth opposite such Buyer&rsquo;s name
in column (3)&nbsp;on the Schedule of Buyers attached hereto at a purchase price of $7.16 per Common Share (as adjusted for stock splits,
stock dividends, recapitalizations, reorganizations, reclassifications, combinations, reverse stock splits or other similar events occurring
with respect to the Company Common Stock after the date hereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
On the Closing Date (as defined below), upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and
each Buyer agrees to purchase, the number of Common Shares at the Purchase Price (as defined below) set forth opposite such Buyer&rsquo;s
name in columns (3)&nbsp;and (4), respectively, of the Schedule of Buyers attached hereto (the &ldquo;<B>Closing</B>&rdquo;), provided,
that in no event shall the number of Common Shares issued and sold at the Closing exceed 19.99% of the outstanding shares of Company
Common Stock immediately prior to the date of this Agreement. The Closing shall occur simultaneously with the signing of this Agreement,
subject to the satisfaction or waiver of the conditions set forth in <U>Section&nbsp;5</U> and <U>Section&nbsp;6</U> in accordance with
this Agreement (the &ldquo;<B>Closing Date</B>&rdquo;), at the offices of DLA Piper LLP (US), 51 John F. Kennedy Parkway, Suite&nbsp;120,
Short Hills, NJ 07078, or at such later date, time or other location as the parties may mutually agree in writing. At or prior to the
Closing, each of the Company and the Buyers shall execute any related agreements or other documents required to be executed as of the
Closing as provided in <U>Section&nbsp;5</U> and <U>Section&nbsp;6</U> below, each dated the Closing Date. The Common Shares shall be
delivered via a book-entry record through the Company&rsquo;s transfer agent. Unless the Company and a Buyer otherwise mutually agree
with respect to such Buyer&rsquo;s Common Shares, at the Closing settlement shall occur on a &ldquo;delivery versus payment&rdquo; basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purchase
Price</U>. The purchase price for the Common Shares to be purchased by each Buyer at the Closing pursuant to this Agreement shall be
the number of Common Shares to be purchased by such Buyer at the Closing multiplied by the per share purchase price set forth in <U>Section&nbsp;1(a)</U>&nbsp;hereof
which amount shall be set forth opposite such Buyer&rsquo;s name in column (4)&nbsp;of the Schedule of Buyers attached hereto (each,
a &ldquo;<B>Purchase Price</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4(a)(2)&nbsp;and
Regulation D</U>. Assuming the accuracy of the representations and warranties of each Buyer and the Company set forth in <U>Section&nbsp;2
</U>and <U>Section&nbsp;3</U>, respectively, the parties acknowledge and agree that the purpose of such representations and warranties
is, among other things, to ensure that the transaction contemplated hereby qualify as a sale of securities under Section&nbsp;4(a)(2)&nbsp;of
the 1933 Act and Rule&nbsp;506 of Regulation D as promulgated by the SEC under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Allocation
of Purchase Price</U>. The Company and each Buyer, as a result of arm&rsquo;s length bargaining, agree that (I)&nbsp;none of the Buyers
nor any of their Affiliates (as defined below) have rendered services to the Company in connection with this Agreement, and (II)&nbsp;except
as otherwise required by a final &ldquo;determination&rdquo; within the meaning of Section&nbsp;1313(a)(1)&nbsp;of the U.S. Internal
Revenue Code of 1986, as amended, all tax returns and other information returns of each party relative to this Agreement, and the Common
Shares issued pursuant hereto shall consistently reflect the matters agreed to in clause (I)&nbsp;of this <U>Section&nbsp;1(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>BUYER&rsquo;S
REPRESENTATIONS AND WARRANTIES</U>. Each Buyer, severally and not jointly, represents and warrants with respect to only itself to the
Company that, as of the date hereof and as of the Closing Date<FONT STYLE="text-transform: uppercase">:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Public Sale or Distribution</U>. Such Buyer is acquiring the Common Shares for its own account, not as nominee or agent, for the purpose
of investment and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant
to sales registered or exempted under the 1933 Act; <U>provided</U>, <U>however</U>, that by making the representations herein, such
Buyer does not agree to hold any of the Common Shares for any minimum or other specific term and reserves the right to dispose of the
Common Shares at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act. Such Buyer is
acquiring the Common Shares hereunder in the ordinary course of its business. Such Buyer does not presently have any agreement or understanding,
directly or indirectly, with any Person to distribute any of the Common Shares. For purposes of this Agreement, &ldquo;<B>Person</B>&rdquo;
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization
and a government or any department or agency thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accredited
Investor.</U> Such Buyer is an accredited investor as that term is defined in Rule&nbsp;501(a)&nbsp;of Regulation D as promulgated by
the SEC under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
General Solicitation</U>. Such Buyer did not learn of the investment in the Common Shares as a result of any general or public advertising
or, to such Buyer&rsquo;s knowledge, general solicitation, or publicly disseminated advertisements or sales literature, including (a)&nbsp;any
advertisement, article, notice or other communication published in any newspaper, magazine, website, or similar media, or broadcast over
television or radio, or (b)&nbsp;any seminar or meeting to which such Buyer was invited by any of the foregoing means of communications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Brokers
and Finders</U>. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest
or claim against or upon the Company or a Buyer for any commission, fee or other compensation pursuant to any agreement, arrangement
or understanding entered into by, on behalf of such Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Short
Sales and Confidentiality Prior to the Date Hereof</U>. Other than consummating the transactions contemplated hereunder, such Buyer has
not, nor has any Person acting on behalf of such Buyer or pursuant to any understanding with such Buyer, directly or indirectly executed
any purchases or sales, including &ldquo;<B>short sales</B>&rdquo; (as defined in Rule&nbsp;200 of Regulation SHO under the 1934 Act),&nbsp;of
the securities of the Company, including any derivatives, during the period commencing as of the time that such Buyer was first contacted
by the Company or any other Person regarding the transactions contemplated hereby and ending immediately prior to the date hereof.&nbsp;
Notwithstanding the foregoing, in the case of a Buyer that is a multi-managed investment vehicle whereby separate portfolio managers
manage separate portions of such Buyer&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Buyer&rsquo;s assets, the representation set forth above shall only apply
with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Common Shares
covered by this Agreement.&nbsp;Other than to other Persons party to this Agreement and other than to such Person&rsquo;s outside attorney,
accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of
the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by
law, as of the date of this Agreement such Buyer has maintained the confidentiality of all disclosures made to it in connection with
this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing
contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability
of, or securing of, available shares to borrow in order to effect &ldquo;short sales&rdquo; or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reliance
on Exemptions</U>. Such Buyer understands that the Common Shares are being offered and sold to it in reliance on specific exemptions
from the registration requirements of U.S. federal and state securities laws and that the Company is relying in part upon the truth and
accuracy of, and such Buyer&rsquo;s compliance with, the representations, warranties, agreements, acknowledgments and understandings
of such Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of such Buyer to acquire
the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Information</U>.
Such Buyer has been furnished with all materials relating to the business, finances and operations of the Company and materials relating
to the transactions contemplated hereunder that have been requested by such Buyer. Such Buyer has been afforded the opportunity to ask
questions of the Company. Neither such inquiries nor any other due diligence investigations conducted by such Buyer or its representatives
shall modify, amend or affect such Buyer&rsquo;s right to rely on the Company&rsquo;s representations and warranties contained herein.
Such Buyer acknowledges that all of the documents filed by the Company with the SEC under Sections 13(a), 14(a)&nbsp;or 15(d)&nbsp;of
the 1934 Act that have been posted on the SEC&rsquo;s EDGAR site are available to such Buyer, and such Buyer has not relied on any statement
of the Company not contained in such documents or in this Agreement (including all schedules attached hereto) in connection with such
Buyer&rsquo;s decision to enter into this Agreement and the transactions contemplated hereby. Such Buyer has not relied on any information
or advice furnished by or on behalf of any other Buyer in connection with the transaction contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Risk</U>.
Such Buyer understands that its investment in the Common Shares involves a high degree of risk. Such Buyer is able to bear the risk of
an investment in the Common Shares, including, without limitation, the risk of total loss of its investment. Such Buyer has sought such
accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to the transactions
contemplated hereby. Such Buyer understands that there is no assurance that the Common Shares will continue to be quoted, traded or listed
for trading or quotation on the Nasdaq Capital Market (&ldquo;<B>Nasdaq</B>&rdquo;) or on any other organized market or quotation system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Governmental Review</U>. Such Buyer understands that no U.S. federal or state agency or any other government or governmental agency has
passed on or made any recommendation or endorsement of the Common Shares or the fairness or suitability of the investment in the Common
Shares nor have such authorities passed upon or endorsed the merits of the offering of the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Residency</U>.
Such Buyer&rsquo;s office in which its investment decision with respect to the Common Shares was made is located at the address immediately
below such Buyer&rsquo;s name on its signature page&nbsp;hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
or Resale</U>. Such Buyer acknowledges and agrees that the Common Shares are &ldquo;restricted securities&rdquo; as defined in Rule&nbsp;144
promulgated under the 1933 Act as in effect from time to time (or a successor rule&nbsp;thereto) (&ldquo;<B>Rule&nbsp;144</B>&rdquo;)
and must be held indefinitely unless they are subsequently registered under the 1933 Act or an exemption from such registration is available.
Such Buyer has been advised or is aware of the provisions of Rule&nbsp;144, which permits limited resale of shares purchased in a private
placement subject to the satisfaction of certain conditions, including, among other things: the availability of certain current public
information about the Company during a certain period of time, if any, the resale occurring following the required holding period under
Rule&nbsp;144 and under certain circumstances the number of shares being sold during any three-month period not exceeding specified limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization;
Validity; Enforcement</U>. Such Buyer has all requisite power and authority to enter into this Agreement and the other Transaction Documents
to which such Buyer is a party, to carry out its obligations hereunder and to consummate the transactions contemplated hereby. This Agreement
and the other Transaction Documents to which such Buyer is a party have been duly and validly authorized, executed and delivered by such
Buyer and shall constitute the legal, valid and binding obligations of such Buyer enforceable against such Buyer in accordance with their
respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors&rsquo;
rights and remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legends</U>.
Such Buyer understands that the certificates or other instruments representing the Common Shares, until such time as the exchange or
resale of the Common Shares have been registered under the 1933 Act, may bear a restrictive legend in the following form (and a stop-transfer
order may be placed against transfer of such Common Shares):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<B>ACT</B>&rdquo;), OR UNDER THE SECURITIES LAWS OF ANY
STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY&nbsp;NOT BE TRANSFERRED OR RESOLD EXCEPT AS
PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE
THAT THEY MAY&nbsp;BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES
MAY&nbsp;REQUIRE AN OPINION OF COUNSEL IN FORM&nbsp;AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED
TRANSFER OR RESALE IS IN COMPLIANCE WITH THE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In addition, if any Buyer is
an affiliate of the Company, the Common Shares issued to such Buyer may bear the following &ldquo;affiliates&rdquo; legend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SHARES REPRESENTED BY THIS CERTIFICATE
ARE HELD BY AN AFFILIATE OF THE ISSUER AS DEFINED IN RULE 144 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<B>ACT</B>&rdquo;),
AND MAY&nbsp;ONLY BE SOLD OR OTHERWISE TRANSFERRED IN COMPLIANCE WITH THE REQUIREMENTS OF RULE 144 OR PURSUANT TO A REGISTRATION STATEMENT
UNDER SAID ACT OR AN EXEMPTION FROM SUCH REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance by such Buyer of this Agreement and the other Transaction Documents to which such
Buyer is a party and the consummation by such Buyer of the transactions contemplated hereby and thereby will not (i)&nbsp;result in a
violation of the organizational documents of such Buyer or (ii)&nbsp;conflict with, or constitute a default (or an event which with notice
or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which such Buyer is a party, or (iii)&nbsp;result in a violation of any law, rule, regulation,
order, judgment or decree (including federal and state securities laws) applicable to such Buyer, except in the case of clauses (ii)&nbsp;and
(iii)&nbsp;above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be
expected to have a material adverse effect on the ability of such Buyer to perform its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Forward
Looking Statements</U>. In connection with the due diligence investigation of the Company by each Buyer, such Buyer has received and
may continue to receive after the date hereof from the Company certain estimates, projections, forecasts, regulatory approval expectations
and other forward-looking information, as well as certain business plan information, regarding the Company and its affiliates and subsidiaries
and their respective businesses and operations. Such Buyer hereby acknowledges and agrees (a)&nbsp;that there are uncertainties inherent
in attempting to make such estimates, projections, forecasts, regulatory approval expectations and other forward-looking statements,
as well as business plans, (b)&nbsp;to take full responsibility for making its own evaluation of the adequacy and accuracy of all such
estimates, projections, forecasts, regulatory approval expectations and other forward-looking statements, as well as such business plans,
so furnished to it (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, forward-looking
statements or business plans), and (c)&nbsp;that the Company has not made and is not making any express or implied representation or
warranty with respect to such estimates, projections, forecasts, regulatory approval expectations, forward-looking statements or business
plans (including the reasonableness of the assumptions underlying such estimates, projections, forecasts, regulatory approval expectations,
forward-looking statements or business plans).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company represents and
warrants to each of the Buyers that, as of the date hereof and as of the Closing Date, except as set forth in the SEC Reports (as defined
below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization
and Qualification</U>. The Company and each of its subsidiaries is an entity duly organized and validly existing and in good standing
under the laws of its jurisdiction of formation, and has the requisite corporate (or other) power and authorization to own its properties
and to carry on its business as now being conducted and as presently proposed to be conducted. The Company and each of its subsidiaries
is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which its ownership of property
or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified
or be in good standing would not reasonably be expected to have a Material Adverse Effect. As used in this Agreement, &ldquo;<B>Material
Adverse Effect</B>&rdquo; means any material adverse effect on (i)&nbsp;the business, properties, assets, liabilities, operations, results
of operations or condition (financial or otherwise) of the Company or any of its subsidiaries, individually or taken as a whole, or (ii)&nbsp;on
the transactions contemplated hereby and the other Transaction Documents or (iii)&nbsp;on the other Transaction Documents or by the agreements
and instruments to be entered into in connection herewith or therewith, or (iv)&nbsp;on the authority or ability of the Company to perform
any of its obligations under any of the Transaction Documents or (v)&nbsp;on the legality, validity, binding effect or enforceability
of any of the Transaction Documents, except that any of the following, either alone or in combination, shall not be deemed a Material
Adverse Effect: (a)&nbsp;effects caused by changes or circumstances affecting general market or other conditions in the U.S. economy
or which are generally applicable to the industry in which the Company operates, provided that such effects are not borne to a materially
disproportionate degree by the Company compared to other companies operating in the same industry as the Company, (b)&nbsp;effects resulting
from or relating to the announcement or disclosure of the sale of the Common Shares or other transactions contemplated by this Agreement,
(c)&nbsp;effects caused by any event, occurrence or condition resulting from or relating to the taking of any action in accordance with
this Agreement or the Transaction Documents, or (d)&nbsp;effects resulting from Hatch-Waxman based litigation relating to the Company&rsquo;s
LIQ861 product candidate, or from any litigation set forth in the SEC Reports. Except as set forth in the SEC Reports , the Company does
not, directly or indirectly, own any of the capital stock or hold an equity or similar interest in any entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization;
Enforcement; Validity</U>. The Company has the requisite corporate power and authority to enter into and perform its obligations under
this Agreement, the Registration Rights Agreement and each of the other agreements entered into by the Company in connection with the
transactions contemplated by this Agreement (collectively, the &ldquo;<B>Transaction Documents</B>&rdquo;) and to issue the Common Shares
in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and the other Transaction Documents by
the Company and the consummation by the Company of the transactions contemplated hereby and thereby, including, without limitation, the
issuance of the Common Shares, have been duly authorized by the Company&rsquo;s Board of Directors and (other than the filing of a Form&nbsp;D
with the SEC and any other filings as may be required by any state securities agencies), no further filing, consent or authorization
is required by the Company, its Boards of Directors or its stockholders. This Agreement and the other Transaction Documents have been
duly executed and delivered by the Company, and constitute the legal, valid and binding obligations of the Company, enforceable against
the Company in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement
of applicable creditors&rsquo; rights and remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Issuance
of Common Shares</U>. The issuance of the Common Shares at the Closing is duly authorized and, upon issuance in accordance with the terms
of the Transaction Documents, the Common Shares shall be validly issued and free from all preemptive or similar rights (except for those
which have been validly waived prior to the date hereof), taxes, liens and charges and other encumbrances with respect to the issue thereof
and the Common Shares shall be fully paid and nonassessable with the holders being entitled to all rights accorded to a holder of Company
Common Stock. Assuming the accuracy of each of the representations and warranties set forth in <U>Section&nbsp;2</U> of this Agreement,
the offer and issuance by the Company of the Common Shares is exempt from registration under the 1933 Act. The offer and issuance of
the Common Shares hereunder will not obligate the Company to issue shares of Company Common Stock or other securities to any other Person
(other than the Buyers) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding
security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Common Shares) will not (i)&nbsp;result
in a violation of the Company&rsquo;s certificate of incorporation, as amended and restated and as in effect on the date hereof or on
the Closing, as applicable (the &ldquo;<B>Certificate of Incorporation</B>&rdquo;), or the Company&rsquo;s bylaws, as amended and restated
and as in effect on the date hereof or on the Closing, as applicable (the &ldquo;<B>Bylaws</B>&rdquo;), or (ii)&nbsp;conflict with, or
constitute a default (or an event which with notice or lapse of time or both would become a default) in any respect under, or give to
others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company
is a party, or (iii)&nbsp;result in a violation of any applicable law, rule, regulation, order, judgment or decree (including foreign,
federal and state securities laws and regulations and the rules&nbsp;and regulations of Nasdaq) applicable to the Company or by which
any property or asset of the Company is bound or affected, except, in the case of clauses (ii)&nbsp;and (iii)&nbsp;above, as would not
have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Consents</U>.
The Company is not required to obtain any consent from, authorization or order of, or make any filing or registration with (other than
the filing of a Form&nbsp;D with the SEC and any other filings as may be required by any state securities agencies), any court, governmental
agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its obligations
under or contemplated by the Transaction Documents, in each case, in accordance with the terms hereof or thereof. All consents, authorizations,
orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected
on or prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Buyer&rsquo;s Purchase of Common Shares</U>. The Company acknowledges and agrees that each Buyer is acting solely in the capacity
of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby and
that, except as set forth <U>in the SEC Reports</U>, no Buyer is (i)&nbsp;an officer or director of the Company, (ii)&nbsp;an &ldquo;affiliate&rdquo;
of the Company (as defined in Rule&nbsp;144) or (iii)&nbsp;to the knowledge of the Company, a &ldquo;beneficial owner&rdquo; (as defined
for purposes of Rule&nbsp;13d-3 of the 1934 Act) of more than 10% of the Company Common Stock. The Company further acknowledges that
no Buyer is acting as a financial advisor or fiduciary of the Company or any other Buyer (or in any similar capacity) with respect to
the Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives
or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such
Buyer&rsquo;s purchase of the Common Shares. The Company further represents to each Buyer that the Company&rsquo;s decision to enter
into the Transaction Documents has been based solely on the independent evaluation by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company, if any, under the 1933 Act and the Securities Exchange Act of 1934, as amended (the &ldquo;<B>1934 Act</B>&rdquo;),
including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the 1934 Act, for the twelve (12) months preceding the date of this Agreement
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred
to herein as the &ldquo;<B>SEC Reports</B>&rdquo;) on a timely basis or has received a valid extension of such time of filing and has
filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all
material respects with the requirements of the 1933 Act and the 1934 Act, as applicable, and none of the SEC Reports, when filed, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the
Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules&nbsp;and regulations
of the Securities Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) with respect thereto as in effect at the time of filing. Such financial
statements have been prepared in accordance with generally accepted accounting principles in the United States (&ldquo;<B>GAAP</B>&rdquo;)
applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not contain all footnotes required by GAAP applied on a consistent basis during
the periods involved, and fairly present in all material respects the financial position of the Company as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments. As of the date of this Agreement and as of the Closing Date, there are no outstanding or unresolved comments
received from the staff of the SEC with respect to the SEC Reports, and to the Company&rsquo;s knowledge, none of the SEC Reports is
the subject of any ongoing SEC review or investigation. No other information provided by or on behalf of the Company to any of the Buyers
which is not included in the SEC Reports, including, without limitation, information referred to in <U>Section&nbsp;2(h)</U>&nbsp;of
this Agreement, contains any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements
therein, in the light of the circumstance under which they are or were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>.
Except as set forth in the SEC Reports, the Company does not have any subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
General Solicitation; Placement Agent&rsquo;s Fees</U>. Neither the Company nor its affiliates, nor any Person acting on their behalf,
has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer
or sale of the Common Shares. There are no placement agent fees, financial advisory fees, or brokers&rsquo; commissions (other than for
Persons engaged by or on behalf of any Buyer or its investment advisor) relating to or arising out of the transactions contemplated hereby
in connection with the sale of the Common Shares. The Company shall pay, and hold each Buyer harmless against, any liability, loss or
expense (including, without limitation, attorney&rsquo;s fees and out-of-pocket expenses) arising in connection with any such claim.
The Company has not engaged any placement agent or other agent in connection with the offer or sale of the Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Integrated Offering</U>. Neither the Company nor any of its affiliates, nor any Person acting on their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration
of the issuance of any of the Common Shares under the 1933 Act, whether through integration with prior offerings or otherwise, or cause
this offering of the Common Shares to require approval of shareholders of the Company for purposes of the 1933 Act or any applicable
shareholder approval provisions, including, without limitation, under the rules&nbsp;and regulations of any exchange or automated quotation
system on which any of the securities of the Company are listed or designated for quotation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Application
of Takeover Protections; Rights Agreement</U>. The Company and its Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill (including, without limitation,
any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation, Bylaws or
other organizational documents or the laws of the jurisdiction of its formation which is or could become applicable to any Buyer as a
result of the transactions contemplated by this Agreement, including, without limitation, the issuance of the Common Shares and any Buyer&rsquo;s
ownership of the Common Shares. The Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable
any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of Company Common Stock or a change
in control of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Certain Changes</U>. Except as disclosed in the SEC Reports, since December&nbsp;31, 2022, there has been no material adverse change
and no material adverse development in the business, assets, liabilities, properties, operations, condition (financial or otherwise),
results of operations or prospects of the Company. Except as disclosed in the SEC Reports, since December&nbsp;31, 2022, the Company
has not (i)&nbsp;declared or paid any dividends or (ii)&nbsp;sold any assets, individually or in the aggregate, in excess of $100,000
outside of the ordinary course of business. The Company has not taken any steps to seek protection pursuant to any law or statute relating
to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company have any knowledge or reason
to believe that any of its creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which
would reasonably lead a creditor to do so. The Company is not as of the date hereof and, after giving effect to the transactions contemplated
hereby to occur at the Closing, will not be Insolvent (as defined below). For purposes of this Agreement, &ldquo;<B>Insolvent</B>&rdquo;
means, with respect to any Person, (i)&nbsp;the present fair saleable value of such Person&rsquo;s assets is less than the amount required
to pay such Person&rsquo;s total Indebtedness (as defined below), (ii)&nbsp;such Person is unable to pay its debts and liabilities, subordinated,
contingent or otherwise, as such debts and liabilities become absolute and matured, (iii)&nbsp;such Person intends to incur or believes
that it will incur debts that would be beyond its ability to pay as such debts mature or (iv)&nbsp;such Person has unreasonably small
capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Undisclosed Events, Liabilities, Developments or Circumstances</U>. No event, liability, development or circumstance has occurred or
exists, or is contemplated to occur with respect to the Company or its business, properties, prospects, operations or financial condition,
that would be required to be disclosed by the Company under applicable securities laws on a registration statement on Form&nbsp;S-1 filed
with the SEC relating to an issuance and sale by the Company of Company Common Stock and which has not been publicly disclosed other
than set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conduct
of Business; Regulatory Permits</U>. The Company is not in violation of any term of or in default under the Certificate of Incorporation
or the Bylaws. The Company is not in violation of any judgment, decree or order or any statute, ordinance, rule&nbsp;or regulation applicable
to the Company, and the Company will not conduct its business in violation of any of the foregoing, except in all cases for possible
violations which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. From November&nbsp;18,
2020 to the date hereof, the Company Common Stock has been designated for quotation on Nasdaq. From November&nbsp;18, 2020 to the date
hereof, (i)&nbsp;trading in the Company Common Stock has not been suspended by the SEC or Nasdaq and (ii)&nbsp;the Company has received
no communication, written or oral, from the SEC or Nasdaq regarding the suspension or delisting of the Company Common Stock from Nasdaq.
The Company and each of its subsidiaries possesses all certificates, authorizations and permits issued by the appropriate foreign, federal
or state regulatory authorities necessary to conduct its business, except where the failure to possess such certificates, authorizations
or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any of its subsidiaries
has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. Without
limiting the generality of the foregoing, the Company has no knowledge of any facts or circumstances that would reasonably lead to delisting
or suspension of Company Common Stock by Nasdaq in the foreseeable future. The Company is in compliance with applicable Nasdaq continued
listing requirements. The issuance and sale of the Common Shares does not contravene the rules&nbsp;and regulations of Nasdaq and shall
not have the effect of delisting or suspending of the Company Common Stock from Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Foreign
Corrupt Practices</U>. Neither the Company nor any director, officer, agent, employee or other Person acting on behalf of the Company
has, in the course of its actions for, or on behalf of, the Company (i)&nbsp;used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment
to any foreign or domestic government official or employee from corporate funds; (iii)&nbsp;violated or is in violation of any provision
of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv)&nbsp;made any unlawful bribe, rebate, payoff, influence payment,
kickback or other unlawful payment to any foreign or domestic government official or employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transactions
with Affiliates</U>. Except for this Agreement or as set forth in the SEC Reports, none of the officers, directors or employees of the
Company is presently a party to any transaction with the Company (other than for ordinary course services as employees, officers or directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real
or personal property to or from, or otherwise requiring payments to or from any such officer, director or employee or, to the knowledge
of the Company, any corporation, partnership, trust or other Person in which any such officer, director, or employee has a substantial
interest or is an employee, officer, director, trustee or partner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Equity
Capitalization</U>. As of September&nbsp;30, 2023, the authorized capital stock of the Company consists of (i)&nbsp;80,000,000 shares
of Company Common Stock, of which as of September&nbsp;30, 2023, 64,899,295 were issued and outstanding, 415,572 were issuable under
outstanding options to purchase Company Common Stock at a weighted average exercise price of $4.79 per share, 1,730,523 shares were issuable
upon the vesting of restricted stock units and, 415,572 shares were issuable under outstanding warrants to purchase Company Common Stock
at a weighted average exercise price of $3.83 per share, and (ii)&nbsp;10,000,000 shares of preferred stock of Company, none of which
are issued or outstanding. Except as disclosed in the SEC Reports (i)&nbsp;none of the Company&rsquo;s capital stock is subject to preemptive
rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company; (ii)&nbsp;there are no outstanding
options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights
convertible into, or exercisable or exchangeable for, any capital stock of the Company, or contracts, commitments, understandings or
arrangements by which the Company is or may become bound to issue additional capital stock of the Company or options, warrants, scrip,
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable
or exchangeable for, any capital stock of the Company; (iii)&nbsp;there are no outstanding debt securities, notes, credit agreements,
credit facilities or other agreements, documents or instruments evidencing Indebtedness of the Company or by which the Company is or
may become bound; (iv)&nbsp;there are no financing statements securing obligations in any amounts filed in connection with the Company;
(v)&nbsp;there are no outstanding securities or instruments of the Company which contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the Company is or may become bound to redeem a security of the
Company; (vi)&nbsp;the Company has no stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan
or agreement; and (vii)&nbsp;the Company has no liabilities or obligations required to be disclosed in the SEC Reports which are not
so disclosed in the SEC Reports, other than those incurred in the ordinary course of the Company&rsquo;s business and which, individually
or in the aggregate, do not or could not have a Material Adverse Effect. All of the issued and outstanding shares of the Company&rsquo;s
capital stock have been duly authorized and validly issued and are fully paid and nonassessable; none of such shares were issued in violation
of any preemptive rights; and such shares were issued in compliance with applicable state and federal securities law and any rights of
third parties. There are no other outstanding warrants, options, convertible securities or other rights, agreements or arrangements of
any character under which the Company is or may be obligated to issue any equity securities of any kind, except as contemplated by this
Agreement. There are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any
kind between the Company and any of its securityholders relating to Company securities held by them. Except as provided in the Registration
Rights Agreement, that certain Registration Rights Agreement, dated as of December&nbsp;23, 2019, by and among Liquidia Technologies,&nbsp;Inc.
and certain Company stockholders signatory thereto, the Registration Rights Agreement, that certain Registration Rights Agreement, dated
as of April&nbsp;12, 2021, by and among Liquidia Technologies,&nbsp;Inc. and certain purchasers signatory thereto, and except as provided
in that certain Seventh Amended and Restated Investors&rsquo; Rights Agreement, dated as of February&nbsp;2, 2018, by and among Liquidia
Technologies,&nbsp;Inc. and certain investors signatory thereto, no Person has the right to require the Company to register any Company
securities under the 1933 Act, whether on a demand basis or in connection with the registration of Company securities for its own account
or for the account of any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Indebtedness
and Other Contracts</U>. Except as disclosed in the SEC Reports, neither the Company nor any of its subsidiaries (i)&nbsp;has any outstanding
Indebtedness, (ii)&nbsp;is a party to any contract, agreement or instrument, the violation of which, or default under which, by the other
party(ies) to such contract, agreement or instrument would reasonably be expected to result in a Material Adverse Effect, (iii)&nbsp;is
in violation of any term of, or in default under, any contract, agreement or instrument relating to any Indebtedness, except where such
violations and defaults would not result, individually or in the aggregate, in a Material Adverse Effect, or (iv)&nbsp;is a party to
any contract, agreement or instrument relating to any Indebtedness, the performance of which, in the judgment of the Company&rsquo;s
officers, has or is expected to have a Material Adverse Effect. For purposes of this Agreement: (x)&nbsp;&ldquo;<B>Indebtedness</B>&rdquo;
of any Person means, without duplication (A)&nbsp;all indebtedness for borrowed money, (B)&nbsp;all obligations issued, undertaken or
assumed as the deferred purchase price of property or services (including, without limitation, &ldquo;finance leases&rdquo; in accordance
with GAAP applied on a consistent basis during the periods involved) (other than trade payables entered into in the ordinary course of
business consistent with past practice), (C)&nbsp;all reimbursement or payment obligations with respect to letters of credit, surety
bonds and other similar instruments, (D)&nbsp;all obligations evidenced by notes, bonds, debentures or similar instruments, including
obligations so evidenced incurred in connection with the acquisition of property, assets or businesses, (E)&nbsp;all indebtedness created
or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any
property or assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such
agreement in the event of default are limited to repossession or sale of such property), (F)&nbsp;all monetary obligations under any
leasing or similar arrangement which, in connection with GAAP applied on a consistent basis during the periods involved is classified
as a finance lease, (G)&nbsp;all indebtedness referred to in clauses (A)&nbsp;through (F)&nbsp;above secured by (or for which the holder
of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, claim, lien, tax, right of first
refusal, pledge, charge, security interest or other encumbrance upon or in any property or assets (including accounts and contract rights)
owned by any Person, even though the Person which owns such assets or property has not assumed or become liable for the payment of such
indebtedness, and (H)&nbsp;all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in
clauses (A)&nbsp;through (G)&nbsp;above; and (y)&nbsp;&ldquo;<B>Contingent Obligation</B>&rdquo; means, as to any Person, any direct
or indirect liability, contingent or otherwise, of that Person with respect to any indebtedness, finance lease, dividend or other obligation
of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide
assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will
be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Litigation</U>. Except as set forth in the SEC Reports, there is no action, suit, proceeding, inquiry or investigation before or by
Nasdaq, any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company,
threatened against or affecting the Company, any of its subsidiaries, Company Common Stock or any of Company&rsquo;s or any of its subsidiaries&rsquo;
officers or directors, whether of a civil or criminal nature or otherwise, in their capacities as such (collectively, the &ldquo;<B>Litigation
Matters</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(t)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Employee
Relations</U>. The Company is not a party to any collective bargaining agreement, nor does it employ any member of a union. The Company
believes that its relations with its employees are good. No executive officer (as defined in Rule&nbsp;501(f)&nbsp;promulgated under
the 1933 Act) or other key employee of the Company has notified the Company that such officer intends to leave the Company or otherwise
terminate such officer&rsquo;s employment with the Company. No executive officer or other key employee of the Company is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement,
non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment of each such
executive officer or other key employee (as the case may be) does not subject the Company to any liability with respect to any of the
foregoing matters. The Company is in compliance with all federal, state, local and foreign laws and regulations respecting labor, employment
and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance
would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(u)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Title</U>.
The Company has good and marketable title in fee simple to all real property and good and marketable title to all personal property owned
by it which is material to the business of the Company, in each case free and clear of all liens, encumbrances and defects except such
as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property
by the Company. Any real property and facilities held under lease by the Company is held by it under valid, subsisting and enforceable
leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property Rights</U>. The Company and each of its subsidiaries owns, free and clear of all liens, encumbrances and defects, or has obtained
valid and enforceable licenses for, all Intellectual Property (as defined below) (i)&nbsp;described in the SEC Reports as being owned
or licensed by it or (ii)&nbsp;which are necessary for the conduct of their respective businesses as currently conducted or as currently
proposed to be conducted, in each case as such business is described in the SEC Reports (collectively, with respect to the Company and/or
any of its subsidiaries, the &ldquo;<B>Company Intellectual Property</B>&rdquo;).&nbsp; To the Company&rsquo;s knowledge:&nbsp; (i)&nbsp;there
are no third parties (including any present or former employees or contractors of the Company or any of its subsidiaries) who have rights
to any Company Intellectual Property, except for customary reversionary rights of third-party licensors, and the conduct of the Company&rsquo;s
or any of its subsidiaries&rsquo; businesses as currently conducted or as currently proposed to be conducted (as such business is described
in the SEC Reports) does not infringe, misappropriate or otherwise violate the Intellectual Property of any third party; and (ii)&nbsp;there
is no infringement, misappropriation or other violation by third parties of any Company Intellectual Property.&nbsp; Except as set forth
in the SEC Reports, there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others:
(A)&nbsp;challenging the Company&rsquo;s or any of its subsidiaries&rsquo; rights in or to any Company Intellectual Property, and the
Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging
the validity, enforceability or scope of any Company Intellectual Property, and the Company is unaware of any facts which would form
a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or any of its subsidiaries
infringes, misappropriates or otherwise violates, or would, upon the commercialization of any product or service described in the SEC
Reports as under development, infringe, misappropriate or otherwise violate, any Intellectual Property rights of others, and the Company
is not aware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim.&nbsp; The Company has complied
in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or
any of its subsidiaries, and all such agreements are in full force and effect.&nbsp; The products or product candidates described in
the SEC Reports (each a &ldquo;<B>Company Product</B>&rdquo;) as under development by the Company or any of its subsidiaries fall within
the scope of the claims of one or more patents or patent applications owned by, or exclusively licensed to, the Company or any of its
subsidiaries, the rights of the Company or any of its subsidiaries under which entitle (or in the case of patent applications, once issued,
would entitle) the Company or any of its subsidiaries to claim in good faith that a third party should cease the manufacture, use, sale
or importation of such Company Product. The Company has taken commercially reasonable efforts to protect, enforce and maintain the material
Company Intellectual Property. All present or former employees, consultants or independent contractors involved the development of any
material Company Intellectual Property have executed written agreements under which he, she or it assigns all rights to such Intellectual
Property to the Company or any of its subsidiaries and agrees to protect Company&rsquo;s and its subsidiaries&rsquo; trade secrets and
other confidential information. The term &ldquo;<B>Intellectual Property</B>&rdquo; means all intellectual property rights, including
inventions, patents, trademarks, trade names, service names,&nbsp;Internet domain names, copyrights, copyrightable works, and trade secrets
and other confidential or proprietary information, and all registration or applications (including, as applicable, any renewals, reissues,
reexaminations, continuations, continuations-in-part, or divisionals thereof) for any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(w)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Environmental
Laws</U>. The Company and each of its subsidiaries (A)&nbsp;is in compliance with all Environmental Laws (as defined below), (B)&nbsp;has
received all permits, licenses or other approvals required of it under applicable Environmental Laws to conduct its business and (C)&nbsp;is
in compliance with all terms and conditions of any such permit, license or approval where, in each of the foregoing clauses (A), (B)&nbsp;and
(C), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The
term &ldquo;<B>Environmental Laws</B>&rdquo; means all federal, state, local or foreign laws relating to pollution or protection of human
health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata),
including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, &ldquo;<B>Hazardous Materials</B>&rdquo;) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Tax
Status</U>. The Company and each of its subsidiaries (i)&nbsp;has timely and properly filed all foreign, federal and state income and
all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has timely paid all taxes
and other governmental assessments and charges that are material in amount, whether or not shown or determined to be due on such returns,
reports and declarations, except those being contested in good faith, and (iii)&nbsp;has set aside on its books provision reasonably
adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
know of no basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(y)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Company Status</U>. Neither the Company nor any of its subsidiaries is, or upon consummation of the sale of the Common Shares, and for
so long as any Buyer holds any Common Shares, will be, an &ldquo;investment company,&rdquo; an affiliate of an &ldquo;investment company,&rdquo;
a company controlled by an &ldquo;investment company&rdquo; or an &ldquo;affiliated person&rdquo; of, or &ldquo;promoter&rdquo; or &ldquo;principal
underwriter&rdquo; for, an &ldquo;investment company&rdquo; as such terms are defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(z)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>U.S.
Real Property Holding Corporation</U>. The Company is not, has never been, and, so long as any Common Shares are held by any of the Buyers,
shall not become, a U.S. real property holding corporation within the meaning of Section&nbsp;897 of the Internal Revenue Code of 1986,
as amended, and the Company shall so certify upon any Buyer&rsquo;s request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(aa)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shell
Company Status</U>. The Company is not, and has never been, an issuer identified in, or subject to, Rule&nbsp;144(i)(1)&nbsp;of the 1933
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(bb)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Anti-Money Laundering Laws</U>. The Company and its affiliates are and have been at all times in compliance with applicable financial
recordkeeping and reporting requirements and all other applicable U.S. and non-U.S. anti-money laundering and anti-terrorism laws, rules&nbsp;and
regulations, including, but not limited to, those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the United
States Bank Secrecy Act, as amended by the USA PATRIOT Act of 2001, and the United States Money Laundering Control Act of 1986 (18 U.S.C.
 &sect;&sect;1956 and 1957), as amended, as well as the implementing rules&nbsp;and regulations promulgated thereunder, and the applicable
money laundering statutes of all applicable jurisdictions, the rules&nbsp;and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any governmental agency or self-regulatory body (collectively, the &ldquo;<B>Anti-Money
Laundering Laws</B>&rdquo;), and no action, suit or proceeding by or before any court or governmental agency, authority or body, self-regulatory
body, or any arbitrator involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company,
threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(cc)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Sanctions Laws</U>. Neither the Company nor any of its directors, officers, employees, representatives, agents, affiliates or other
Persons acting on behalf of the Company or any of its affiliates is, or is directly or indirectly owned or controlled by, a Person that
is currently the subject or the target of any economic or financial sanctions or trade embargoes imposed, administered or enforced by
the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;<B>OFAC</B>&rdquo;)
or the U.S. Departments of State or Commerce and including, without limitation, the designation as a &ldquo;<B>Specially Designated National</B>&rdquo;
or on the &ldquo;<B>Sectoral Sanctions Identifications List</B>&rdquo;, collectively &ldquo;<B>Blocked Persons</B>&rdquo;), the United
Nations Security Council, the European Union, His Majesty&rsquo;s Treasury or any other relevant sanctions authority (collectively, &ldquo;<B>Sanctions
Laws</B>&rdquo;); neither the Company nor any of its directors, officers, employees, representatives, agents, affiliates or other Persons
acting on behalf of the Company or its affiliates, is located, organized or resident in a country or territory that is the subject or
target of a comprehensive embargo or Sanctions Laws prohibiting trade with the country or territory, including, without limitation, the
so-called Donetsk People&rsquo;s Republic, the so-called Luhansk People&rsquo;s Republic, the Crimea Region and the non-government controlled
areas of the Zaporizhzhia and Kherson Regions of Ukraine, Cuba,&nbsp;Iran, North Korea and Syria (each, a &ldquo;<B>Sanctioned Country</B>&rdquo;);
neither the Company nor any of its directors, officers, employees, representatives, agents, affiliates or other Persons acting on behalf
of the Company or its affiliates, has violated or is in violation of any applicable Sanctions Laws, including but not limited to the
Sanctions Laws of the United States; the Company maintains in effect and enforces policies and procedures reasonably designed to ensure
compliance by the Company and its affiliates with applicable Sanctions Laws; neither the Company nor any of its directors, officers,
employees, representatives, agents, affiliates or other Persons acting on behalf of the Company or its affiliates, acting in any capacity
in connection with the operations of the Company, conducts any business with or for the benefit of any Blocked Person or engages in making
or receiving any contribution of funds, goods or services to, from or for the benefit of any Blocked Person, or deals in, or otherwise
engages in any transaction relating to, any property or interests in property blocked or subject to blocking or rejection pursuant to
any applicable Sanctions Laws; neither the Company nor its affiliates derives revenues from investments in, or transactions with, Blocked
Persons or Sanctioned Countries in violation of Sanctions Laws; no action of the Company in connection with (i)&nbsp;the execution, delivery
and performance of this Agreement and the other Transaction Documents, (ii)&nbsp;the issuance and sale of the Common Shares, or (iii)&nbsp;the
direct or indirect use of proceeds from the Common Shares or the consummation of any other transaction contemplated hereby or by the
other Transaction Documents or the fulfillment of the terms hereof or thereof, will result in the proceeds of the transactions contemplated
hereby and by the other Transaction Documents being used, or loaned, contributed or otherwise made available, directly or indirectly,
to any joint venture partner or other Person or entity, for the purpose of (i)&nbsp;unlawfully funding or facilitating any activities
of or business with any Person that, at the time of such funding or facilitation, is the subject or target of Sanctions Laws, (ii)&nbsp;unlawfully
funding or facilitating any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in
a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise)
of Sanctions Laws. From its inception, the Company has not knowingly engaged in and is not now knowingly engaged in any dealings or transactions
in violation of any Sanctions Laws or with any Person that at the time of the dealing or transaction is or was the subject or the target
of Sanctions Laws or with any Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(dd)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Anti-Bribery Laws</U>. The Company has not made any contribution or other payment, or offered to make such contribution or payment,
to any official of, or candidate for, any federal, state or foreign office in violation of any law. Neither the Company nor any of its
affiliates, nor any directors, officers, agents, employees or other Persons acting on behalf of the Company or any of its affiliates,
has (i)&nbsp;used any funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity,
(ii)&nbsp;made any direct or indirect unlawful payment to any foreign or domestic government official or employee, to any employee or
agent of a private entity with which the Company or any of its affiliates does or seeks to do business or to foreign or domestic political
parties or campaigns, (iii)&nbsp;violated or is in violation of any provision of any applicable law or regulation implementing the OECD
Convention on Combating Bribery of Foreign Public Officials in International Business Transactions or any applicable provision of the
U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other similar applicable law of any other jurisdiction,
including laws of any jurisdiction in which the Company or its affiliates operate their business, including, in each case, the rules&nbsp;and
regulations thereunder (the &ldquo;<B>Anti-Bribery Laws</B>&rdquo;), (iv)&nbsp;taken, is currently taking or will take any action in
furtherance of an offer, payment, gift or anything else of value, directly or indirectly, to any Person while knowing that all or some
portion of the money or value will be offered, given or promised to anyone to improperly influence official action, to obtain or retain
business or otherwise to secure any improper advantage or (v)&nbsp;otherwise made any offer, bribe, rebate, payoff, influence payment,
unlawful kickback or other unlawful payment; the Company and its affiliates have instituted and have maintained, and will continue to
maintain, as applicable, policies and procedures reasonably designed to promote and achieve compliance with the laws referred to in (iii)&nbsp;above
and with this representation and warranty; neither the Company nor any of its affiliates will directly or indirectly use the proceeds
of the Common Shares or lend, contribute or otherwise make available such proceeds to any subsidiary, affiliate, joint venture partner
or other Person for the purpose of financing or facilitating any activity that would violate the laws and regulations referred to in
(iii)&nbsp;above; there are, and have been, no allegations, investigations or inquiries with regard to a potential violation of any Anti-Bribery
Laws by the Company or its affiliates, or any of their respective current or former directors, officers, employees, stockholders, representatives
or agents, or other Persons acting or purporting to act on their behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ee)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Disqualification Events</U>. Neither the Company nor any of its predecessors, any affiliated issuer, any director, executive officer,
other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding
voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule&nbsp;405 under the
1933 Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;<B>Issuer Covered Person</B>&rdquo; and, together,
 &ldquo;<B>Issuer Covered Persons</B>&rdquo;) is subject to any Disqualification Event, except, if applicable, for a Disqualification
Event as to which Rule&nbsp;506(d)(2)(ii)&nbsp;or (iii)&nbsp;or (d)(3)&nbsp;is applicable. The Company has exercised reasonable care
to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable,
with its disclosure obligations under Rule&nbsp;506(e), and has furnished to the Buyers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ff)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(gg)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
Controls</U>. The Company maintains systems of internal accounting controls designed to provide reasonable assurance that (a)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorizations; (b)&nbsp;transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP applied on a consistent basis during the periods involved and to
maintain asset accountability; (c)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific
authorization; and (d)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences. Other than as set forth in the SEC Reports, the Company is not aware of any material
weaknesses or significant deficiencies in its internal control over financial reporting. To the knowledge of the Company, since the date
of the latest audited financial statements of the Company included within the SEC Reports, there has been no change in the Company&rsquo;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s
internal control over financial reporting. The Company has established disclosure controls and procedures (as defined in 1934 Act Rules&nbsp;13a-15
and 15d-15) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the
Company is made known to the certifying officers by others within the Company, particularly during the period in which the Company&rsquo;s
Annual Report on Form&nbsp;10-K or Quarterly Report on Form&nbsp;10-Q, as the case may be, is being prepared. The Company&rsquo;s certifying
officers evaluated the effectiveness of the Company&rsquo;s controls and procedures as of a date within 90 days prior to the filing date
of the Annual Report on Form&nbsp;10-K for the fiscal year most recently ended (such date, the &ldquo;<B>Evaluation Date</B>&rdquo;).
The Company presented in its Annual Report on Form&nbsp;10-K for the fiscal year most recently ended the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since
the Evaluation Date, there have been no significant changes in the Company&rsquo;s internal controls (as such term is defined in Item
307(b)&nbsp;of Regulation S-K under the 1933 Act) or, to the Company&rsquo;s knowledge, in other factors that would significantly adversely
affect the Company&rsquo;s internal controls. To the knowledge of the Company, the Company&rsquo;s &ldquo;internal control over financial
reporting&rdquo; and &ldquo;disclosure controls and procedures&rdquo; (as such terms are defined under the 1934 Act) are effective at
a reasonable assurance level.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(hh)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Clinical
Data and Regulatory Compliance</U>.&nbsp; The preclinical tests and clinical trials, and other studies (collectively, &ldquo;<B>studies</B>&rdquo;)
that are described in, or the results of which are referred to in, the SEC Reports were and, if still pending, are being conducted in
all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard
medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material
respects and fairly presents the data derived from such studies, and the Company does not have any knowledge of any other studies the
results of which are materially inconsistent with, or otherwise call into question, the results described or referred to in the SEC Reports.
Each of the Company and its subsidiaries has made all such filings and obtained all such approvals as may be required by the Food and
Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government
or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the &ldquo;<B>Regulatory
Agencies</B>&rdquo;) based on the location and nature of the relevant study; the Company has not received any notice of, or correspondence
from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred
to in the SEC Reports; and each of the Company and its subsidiaries has operated and currently is in compliance in all material respects
with all applicable rules, regulations and policies of the Regulatory Agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Health Care and Privacy Laws</U>.&nbsp; Each of the Company and its subsidiaries is, and at all times has been, in material compliance
with all applicable Health Care and Privacy Laws.&nbsp;For purposes of this Agreement, &ldquo;<B>Health Care and Privacy Laws</B>&rdquo;
means:&nbsp;(i)&nbsp;the Federal&nbsp;Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii)&nbsp;all applicable
federal, state, local and foreign health care laws, including, without limitation, the U.S.&nbsp;Anti-Kickback Statute (42&nbsp;U.S.C.&nbsp;Section&nbsp;1320a-7b(b)),&nbsp;the
Civil Monetary Penalties Law (42 U.S.C. Section&nbsp;1320a-7a),&nbsp;the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et
seq.), all applicable federal, state, local and all foreign criminal laws relating to health care fraud and abuse, including but not
limited to the U.S. False Statements Law (42 U.S.C.&nbsp;Section&nbsp;1320a-7b(a)),&nbsp;18 U.S.C. Sections 286 and 287, and the health
care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&ldquo;<B>HIPAA</B>&rdquo;)
(42 U.S.C. Section&nbsp;1320d et seq.), the exclusion laws (42 U.S.C. Section&nbsp;1320a-7), the statutes, regulations and directives
of applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such statutes; (iii)&nbsp;to
the extent applicable, the Standards for Privacy of Individually Identifiable Health Information (the &ldquo;<B>Privacy Rule</B>&rdquo;),
the Security Standards, and the Standards for Electronic Transactions and Code Sets promulgated under HIPAA,&nbsp;the Health Information
Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), and the regulations promulgated thereunder and
any state or&nbsp;non-U.S.&nbsp;counterpart&nbsp;thereof or other law or regulation the purpose of which is to protect the privacy of
individuals or prescribers; (iv)&nbsp;the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education
Reconciliation Act of 2010, the regulations promulgated thereunder; (v)&nbsp;the U.S.&nbsp;Controlled Substances Act (21 U.S.C. Section&nbsp;801
et seq.); (vi)&nbsp;licensure,&nbsp;quality, safety and accreditation requirements under applicable federal, state, local or foreign
laws or regulatory bodies; and (vii)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the
regulation of the Company, including any of the foregoing concerning data security or privacy (including the collection, use, storage,
processing or disposal of any information that identifies or could reasonably be used to identify any natural Person). Neither the Company
nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other material action from any court or arbitrator or governmental or regulatory authority or third party alleging that
any product, operation or activity is in violation of any Health Care and Privacy Laws nor is any such claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action threatened. Each of the Company and each of its subsidiaries has filed,
obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments as required by any Health Care and Privacy Laws, and all such reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments were in all material respects timely, complete, accurate and not misleading on the
date filed (or were corrected or supplemented by a subsequent submission). Neither the Company or any of its subsidiaries has received
written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation is a party to any corporate integrity agreements,
monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority.
Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers or directors has been excluded,
suspended or debarred from participation in any U.S. federal health care program or human clinical research or is subject to a governmental
inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or
exclusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(jj)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(kk)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Manipulation
of Price</U>.&nbsp; Neither the Company nor, to the knowledge of the Company, any Person acting on its behalf, directly or indirectly,
(i)&nbsp;has taken any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Common Shares, (ii)&nbsp;sold, bid for, purchased, or paid any compensation for
soliciting purchases of, any of the Common Shares, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ll)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Eligibility
for Registration</U>. As of the Closing, the Company is eligible to register the Common Shares for resale by the Buyers using Form&nbsp;S-3
promulgated under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(mm)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Taxes</U>. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to be paid
in connection with the issuance, sale and transfer of the Common Shares to be sold to each Buyer hereunder will be, or will have been,
fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(nn)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Bank
Holding Company Act</U>. Neither the Company nor any of its subsidiaries or affiliates is subject to the Bank Holding Company Act of
1956, as amended (the &ldquo;<B>BHCA</B>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<B>Federal
Reserve</B>&rdquo;). Neither the Company nor any of its subsidiaries or affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of
a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its subsidiaries
or affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(oo)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
As applicable, each of the Company and its subsidiaries is insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company
and its subsidiaries are engaged. Neither the Company nor any of its subsidiaries have been refused any insurance coverage sought or
applied for and neither the Company nor any of its subsidiaries has any reason to believe that it will be unable to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue
its business at a cost that would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(pp)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley
Act</U>. The Company is in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are
effective as of the date hereof, and any and all applicable rules&nbsp;and regulations promulgated by the SEC thereunder that are effective
as of the date hereof, except where the failure to be in such compliance would not have, individually or in the aggregate, a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(qq)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Off
Balance Sheet Arrangements</U>. There is no transaction, arrangement, or other relationship between the Company or any of its subsidiaries
and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its 1934 Act filings and is
not so disclosed or that otherwise would be reasonably likely to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">COVENANTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Commercially
Reasonable Efforts</U>. Each party shall use its commercially reasonable efforts timely to satisfy each of the covenants and the conditions
to be satisfied by it as provided in <U>Section&nbsp;5</U> and <U>Section&nbsp;6</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflicting Agreements</U>. The Company will not take any action, enter into any agreement or make any commitment that would conflict
or interfere in any respect with the Company&rsquo;s obligations to the Buyers under the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Nasdaq
Listing</U>. Until the date the Buyers have sold all of the Common Shares (the &ldquo;<B>Reporting Period</B>&rdquo;), the Company will
use commercially reasonable efforts to continue the listing and trading of Company Common Stock on Nasdaq, and, in accordance therewith,
will use commercially reasonable efforts to comply with the Company&rsquo;s reporting, filing and other obligations under the bylaws
or rules&nbsp;of such market or exchange, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reporting
Status</U>. During the Reporting Period, the Company shall timely file all reports required to be filed with the SEC pursuant to the
1934 Act, and the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act
or the rules&nbsp;and regulations thereunder would otherwise permit such termination and the Company shall take all actions necessary
to maintain its eligibility to register the Common Shares for resale by the Buyers on Form&nbsp;S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
or Resale</U>. Notwithstanding any other provision of the Transaction Documents, each Buyer covenants that the Common Shares may be disposed
of only pursuant to an effective registration statement under, and in compliance with the requirements of, the 1933 Act, or pursuant
to an available exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act, and in compliance
with any applicable state and federal securities laws. In connection with any transfer of the Common Shares other than (i)&nbsp;pursuant
to an effective registration statement, (ii)&nbsp;pursuant to Rule&nbsp;144 at a time when the transferor is not at the time of the sale,
or during the ninety (90) days immediately preceding such sale, an affiliate of the Company, or (iii)&nbsp;to the Company, the Company
may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of such transferred Common Shares under the 1933 Act. Notwithstanding the foregoing, provided that no affiliate
of such Buyer serves on the Board of Directors of the Company, the Common Shares may be pledged in connection with a bona fide margin
account or other loan or financing arrangement secured by the Common Shares and such pledge of Common Shares shall not be deemed to be
a transfer, sale or assignment of the Common Shares hereunder, and no such Buyer effecting a pledge of Common Shares shall be required
to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other
Transaction Document, including, without limitation, this <U>Section&nbsp;4(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Removal
of Legends</U>. Subject to the Company&rsquo;s right to request an opinion of counsel as set forth in <U>Section&nbsp;4(e)</U>, the legend
set forth in <U>Section&nbsp;2(o)</U>&nbsp;shall be removed and the Company shall issue or cause to be issued a certificate or book-entry
evidence of ownership without such legend or any other legend (except for any &ldquo;affiliates&rdquo; legend as set forth in <U>Section&nbsp;2(o)</U>&nbsp;to
the extent applicable) to the holder of the applicable Common Shares upon which it is stamped, if (i)&nbsp;such Common Shares are registered
for resale pursuant to an effective registration statement under the 1933 Act, (ii)&nbsp;such Common Shares are eligible to be sold pursuant
to Rule&nbsp;144 at a time the transferor is not, and has not been for ninety (90) days prior to such time, an affiliate of the Company
or (iii)&nbsp;such Common Shares are sold or transferred in compliance with Rule&nbsp;144, including without limitation in compliance
with the current public information requirements of Rule&nbsp;144 if applicable to the Company at the time of such sale or transfer,
and, in the cases of clauses (ii)&nbsp;and (iii), the holder and its broker have delivered customary documents reasonably requested by
counsel to the Company in connection with such sale or transfer, provided that such documents shall not include a legal opinion if the
Common Shares are proposed to be as described in clauses (i), (ii)&nbsp;or (iii)&nbsp;set forth in <U>Section&nbsp;4(e)</U>. Any fees
(with respect to the counsel to the Company or otherwise) associated with the removal of such legend shall be borne by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Use
of Proceeds</U>. The Company shall use the proceeds from the sale of the Common Shares in a manner consistent with the Company&rsquo;s
public statements and filings and for general corporate purposes, but not for (i)&nbsp;the repayment of any outstanding Indebtedness
(other than in connection with the potential refinancing of the Company&rsquo;s credit facility existing on the date hereof) or (ii)&nbsp;the
redemption or repurchase of any equity securities (other than in connection with net issuances pursuant to the Company&rsquo;s equity
plans existing on the date hereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fees</U>.
The Company and the Buyers shall each pay the fees and expenses of their respective advisers, counsel, accountants and other experts,
if any, and all other expenses incurred by such party in connection with the negotiation, preparation, execution, delivery and performance
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Short
Sales and Confidentiality After the Date Hereof</U>. &nbsp;Each Buyer covenants that neither it nor any Affiliates acting on its behalf
or pursuant to any understanding with it will execute any &ldquo;short sales&rdquo; during the period from the date hereof until the
earlier of such time as (i)&nbsp;the transactions contemplated by this Agreement are first publicly announced or (ii)&nbsp;this Agreement
is terminated in full. Each Buyer covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed
by the Company, such Buyer will maintain the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction), other than to such Person&rsquo;s outside attorney, accountant, auditor or investment advisor
only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting,
financial, legal, or administrative tasks and services and other than as may be required by law. Notwithstanding the foregoing, for avoidance
of doubt, nothing contained herein shall preclude any actions with respect to the identification of the availability of, or securing
of, available shares to borrow in order to effect &ldquo;short sales&rdquo; or similar transactions in the future. Each Buyer understands
and acknowledges that the SEC currently takes the position that coverage of &ldquo;short sales&rdquo; of shares of the Common Stock &ldquo;against
the box&rdquo; prior to effectiveness of a resale registration statement with securities included in such registration statement would
be a violation of Section&nbsp;5 of the 1933 Act, as set forth in Item 239.10 of the Securities Act Rules&nbsp;Compliance and Disclosure
Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Form&nbsp;D
and Blue Sky</U>. The Company agrees to file a Form&nbsp;D with respect to the Common Shares as required under Regulation D and to provide
a copy thereof to each Buyer promptly after such filing. The Company shall, on or before the Closing Date, take such action as the Company
shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Common Shares for sale to the Buyers at
the Closing pursuant to this Agreement under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States
(or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Buyers on or prior
to the Closing Date. The Company shall make all filings and reports relating to the offer and sale of the Common Shares required under
applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States following the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Integrated Offering</U>. None of the Company, its affiliates nor any Person acting on their behalf will take any action or steps that
would require registration of the issuance of any of the Common Shares under the 1933 Act or cause the offering of any of the Common
Shares to be integrated with other offerings for purposes of any such applicable shareholder approval provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration
Rights</U>. Upon the written request by such Buyer, the Company agrees to promptly file with the SEC a resale Registration Statement
on Form&nbsp;S-3 or such other appropriate form for an offering to be made on a delayed or continuous basis pursuant to Rule&nbsp;415
pursuant to which all of the Common Shares sold at the Closing to such Buyer shall be registered for resale by such Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CONDITIONS
TO THE COMPANY&rsquo;S OBLIGATION TO ISSUE AND SELL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The obligation of the Company
hereunder to issue and sell the Common Shares at the Closing is subject to the satisfaction, at or before the Closing Date, of each of
the following conditions, <U>provided</U> that these conditions are for the Company&rsquo;s sole benefit and may be waived by the Company
at any time in its sole discretion by providing each Buyer with prior written notice thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Purchase Price for the Common Shares with respect to each Buyer shall have been received by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
representations and warranties made by such Buyer in this Agreement shall be true and correct as of the date hereof and on and as of
the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date which shall
be true and correct as of such specified date); and such Buyer shall have performed, satisfied and complied in all respects with the
covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by such Buyer at or prior
to such Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that
are required in connection with the lawful issuance and sale of the Common Shares pursuant to this Agreement shall be obtained and effective
as of the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Buyer shall have duly executed and delivered to the Company a lock-up agreement in the form of <U>Exhibit&nbsp;A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CONDITIONS
TO EACH BUYER&rsquo;S OBLIGATION TO PURCHASE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The obligation of each Buyer
hereunder to purchase the Common Shares at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the
following conditions, <U>provided</U> that these conditions are for each Buyer&rsquo;s sole benefit and may be waived by such Buyer at
any time in its sole discretion by providing the Company with prior written notice thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have duly executed and delivered to such Buyer (A)&nbsp;each of the Transaction Documents and (B)&nbsp;the Common Shares
(allocated in such amounts as such Buyer shall request), being purchased by such Buyer at the Closing pursuant to this Agreement as is
set forth opposite such Buyer&rsquo;s name in column (3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
connection with the Closing, the Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing
of the Common Shares to be purchased at the Closing, and Nasdaq shall have raised no objection to the consummation of the transactions
contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court
or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted
by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction
Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intentionally
Omitted.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect
to public trading in the Company Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that
are required in connection with the lawful issuance and sale of the Common Shares pursuant to this Agreement, including, without limitation
of Nasdaq, shall be obtained and effective as of the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company Common Stock (I)&nbsp;shall be designated for quotation or listed on Nasdaq and (II)&nbsp;shall not have been suspended, as of
the Closing Date, by the SEC or Nasdaq from trading on Nasdaq nor shall suspension by the SEC or Nasdaq have been threatened, as of the
Closing Date, either (A)&nbsp;in writing by the SEC or Nasdaq or (B)&nbsp;by falling below the minimum listing maintenance requirements
of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall have provided to such Buyer the Company&rsquo;s wire instructions, on letterhead of the Company and executed by the Chief
Executive Officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">TERMINATION
OF OBLIGATIONS TO EFFECT CLOSING; EFFECTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The obligations of the Company,
on the one hand, and the Buyers, on the other hand, to effect the Closing shall terminate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
the mutual written consent of the Company and Buyers that agreed to purchase a majority of the Common Shares to be issued and sold pursuant
to this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">By
the Company if any of the conditions set forth in <U>Section&nbsp;5</U> shall have become incapable of fulfillment, and shall not have
been waived by the Company; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">By
a Buyer (with respect to itself only) if any of the conditions set forth in <U>Section&nbsp;6</U> shall have become incapable of fulfillment,
and shall not have been waived in writing by such Buyer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>provided</U>, <U>however</U>, <U>that</U>,
except in the case of clause (i)&nbsp;above, the party seeking to terminate its obligation to effect the Closing shall not then be in
breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents
if such breach has resulted in the circumstances giving rise to such party&rsquo;s seeking to terminate its obligation to effect the
Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of termination by the Company or
any Buyer of its obligations to effect a Closing pursuant to this <U>Section&nbsp;7</U>, written notice thereof shall be given to the
other Buyers by the Company and any Buyer shall have the right to terminate its obligations to effect the Closing upon written notice
to the Company. Nothing in this <U>Section&nbsp;7</U> shall be deemed to release any party from any liability for any breach by such
party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel
specific performance by any other party of its obligations under this Agreement or the other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>INTENTIONALLY
OMITTED.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">MISCELLANEOUS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law; Jurisdiction; Jury Trial</U>. This Agreement and any related dispute shall be governed by, and construed and interpreted in accordance
with, the laws of the State of New York applicable to contracts executed in and to be performed in that State, without giving effect
to any choice of law or conflict of law provision or rule&nbsp;(whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. Each of the parties hereto hereby (a)&nbsp;irrevocably
submits to the personal jurisdiction of the Supreme Court of the State of New York and any state appellate court therefrom within the
State of New York (or, if the Supreme Court of the State of New York declines to accept jurisdiction over a particular matter, any state
or federal court within the State of New York) in the event that any dispute arises out of this Agreement or any of the transactions
contemplated by this Agreement, (b)&nbsp;agrees that it will not attempt to deny or defeat such personal jurisdiction or venue by motion
or other request for leave from any such court and (c)&nbsp;agrees that it will not bring any action relating to this Agreement or any
of the transactions contemplated by this Agreement in any court other than the Supreme Court of the State of New York and any state appellate
court therefrom within the State of New York (or, if the Supreme Court of the State of New York declines to accept jurisdiction over
a particular matter, any state or federal court within the State of New York). <B>EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES,
TO THE EXTENT PERMITTED BY APPLICABLE LEGAL REQUIREMENTS, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR OTHER LEGAL PROCEEDING
ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; <U>provided</U> that a facsimile,
..pdf or any other electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com) shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not
a facsimile, .pdf or other electronic signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest
extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity
of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change,
the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the
provision(s)&nbsp;in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the
practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations
to replace the prohibited, invalid or unenforceable provision(s)&nbsp;with a valid provision(s), the effect of which comes as close as
possible to that of the prohibited, invalid or unenforceable provision(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement; Amendments</U>. This Agreement and the other Transaction Documents supersede all other prior oral or written agreements between
the Company, its affiliates and Persons acting on their behalf, on the one hand, and the Buyers, their affiliates and Persons acting
on their behalf, on the other hand, with respect to the matters discussed herein, and this Agreement, the other Transaction Documents
and the instruments referenced herein and therein contain the entire understanding of the parties with respect to the matters covered
herein and therein and, except as specifically set forth herein or therein, neither the Company nor any Buyer makes any representation,
warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be amended other than by an instrument
in writing signed by the Company and the Required Holders, and any amendment to this Agreement made in conformity with the provisions
of this <U>Section&nbsp;9(e)</U>&nbsp;shall be binding on all Buyers and permitted assignees Common Shares and the Company; <U>provided</U>,
that any such amendment or waiver that complies with the foregoing but that disproportionately, materially and adversely affects the
rights and obligations of any Buyer relative to the comparable rights and obligations of the other Buyers shall require the prior written
consent of such adversely affected Buyer (for the avoidance of doubt, participation by any Buyer in an unrelated financing by the Company
shall not be deemed to disproportionately affect the Buyers who do not participate in such financing). No provisions hereto may be waived
other than by an instrument in writing signed by the party against whom enforcement is sought. No such amendment shall be effective to
the extent that it applies to less than all of the Buyers or holders of the applicable Common Shares then outstanding. No consideration
shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents
unless the same consideration (other than the reimbursement of legal fees) also is offered to all of the parties to the Transaction Documents
and holders of Common Shares, as the case may be. As used in this Agreement. &ldquo;<B>Required Holders</B>&rdquo; means Buyers or permitted
assignees of at least a majority of the aggregate amount of Common Shares issued and/or issuable hereunder and shall include the Lead
Investor so long as the Lead Investor or any of its Affiliates holds any Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement or any of
the other Transaction Documents must be in writing and will be deemed to have been delivered: (i)&nbsp;upon receipt, when delivered personally;
(ii)&nbsp;upon delivery, when sent by electronic mail (<U>provided</U>, that the sending party does not receive an automated rejection
notice); or (iii)&nbsp;one (1)&nbsp;Business Day after deposit with an overnight courier service, in each case properly addressed to
the party to receive the same. The addresses and e-mail addresses for such communications shall be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to the Company:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Liquidia Corporation</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">419 Davis Drive, Suite&nbsp;100</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Morrisville, NC 27560</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Telephone: (919) 328-4400</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: General Counsel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy (for informational purposes only) to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">DLA Piper LLP (US)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">51 John F. Kennedy Parkway, Suite&nbsp;120</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Short Hills, NJ 07078</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Telephone: (973) 520-2553</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Facsimile: (973) 520-2573</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Andrew P. Gilbert,&nbsp;Esq.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to a Buyer, to its address and e-mail address
set forth on the <U>Schedule of Buyers</U> attached hereto, with copies to such Buyer&rsquo;s representatives as set forth on the <U>Schedule
of Buyers</U> attached hereto, or to such other address and/or e-mail address and/or to the attention of such other Person as the recipient
party has specified by written notice given to each other party five (5)&nbsp;calendar days prior to the effectiveness of such change.
Written confirmation of receipt (A)&nbsp;given by the recipient of such notice, consent, waiver or other communication, (B)&nbsp;mechanically
or electronically generated by the sender&rsquo;s e-mail containing the time and date or (C)&nbsp;provided by an overnight courier service
shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with
clause (i), (ii)&nbsp;or (iii)&nbsp;above, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns,
including any purchasers of the Common Shares. The Company shall not assign this Agreement or any rights or obligations hereunder without
the prior written consent of the Buyers. No Buyer may assign this Agreement or any rights or obligations hereunder without the prior
written consent of the Company except to such Buyer&rsquo;s affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Third
Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except that each Indemnitee shall
have the right to enforce the obligations of the Company with respect to <U>Section&nbsp;8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The representations and warranties of the Buyers and the Company contained in <U>Section&nbsp;2</U> and <U>Section&nbsp;3</U>, respectively,
and the agreements and covenants set forth in <U>Section&nbsp;4</U>, <U>Section&nbsp;8</U> and this <U>Section&nbsp;9</U> shall survive
the Closing. The Company and each Buyer shall be responsible only for its own representations, warranties, agreements and covenants hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Further
Assurances</U>. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Strict Construction</U>. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules&nbsp;of strict construction will be applied against any party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
Each Buyer and each holder of the Common Shares shall have all rights and remedies set forth in the Transaction Documents and all rights
and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such
holders have under any law. The parties agree that irreparable damage may occur in the event that any of the provisions of the Transaction
Documents were not performed in accordance with their specific terms or were otherwise breached and that monetary damages may not be
adequate compensation for any loss incurred by the Buyers or the Company by reason of any breach of any such provisions. As such, the
non-breaching party shall be entitled to seek equitable relief, including an injunction and specific performance, as a remedy for any
such breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Buyers&rsquo; Obligations and Rights</U>. The obligations of each Buyer under any Transaction Document are several and not
joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of
any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by
any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and the Company acknowledges that the Buyers do not
so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Buyers are
in any way acting in concert or as a group, and the Company shall not assert any such claim with respect to such obligations or the transactions
contemplated by the Transaction Documents and the Company acknowledges that the Buyers are not acting in concert or as a group with respect
to such obligations or the transactions contemplated by the Transaction Documents. The Company acknowledges and each Buyer confirms that
it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors.
Each Buyer shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of
this Agreement or out of any other Transaction Documents, and it shall not be necessary for any other Buyer to be joined as an additional
party in any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Waiver
of Conflicts</U>. Each Buyer acknowledges that: (a)&nbsp;it has read this Agreement; (b)&nbsp;it has been represented in the preparation,
negotiation and execution of this Agreement by legal counsel of its own choice or has voluntarily declined to seek such counsel; and
(c)&nbsp;it understands the terms and consequences of this Agreement and is fully aware of the legal and binding effect of this Agreement.
Each Buyer understands that the Company has been represented in the preparation, negotiation and execution of this Agreement by DLA Piper
LLP (US) and that DLA Piper LLP (US) now or may in the future represent one or more Buyers or their affiliates in matters unrelated to
the transactions contemplated by this Agreement, including the representation of such Buyers or their affiliates in matters of a nature
similar to those contemplated by this Agreement. The Company and each Buyer hereby acknowledge that they have had an opportunity to ask
for and have obtained information relevant to such representation, including disclosure of the reasonably foreseeable adverse consequences
of such representation, and hereby waives any conflict arising out of such representation solely with respect to the matters contemplated
by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Publicity</U>.
Except as set forth below, no public release or announcement concerning the transactions contemplated hereby shall be issued by the Buyers
without the prior consent of the Company, except as such release or announcement may be required by law or the applicable rules&nbsp;or
regulations of any securities exchange or securities market, in which case the Buyers shall allow the Company reasonable time to comment
on such release or announcement in advance of such issuance. Notwithstanding the foregoing, each Buyer may identify the Company, the
transactions contemplated by the Transaction Documents and the value of such Buyer&rsquo;s security holdings in the Company in accordance
with applicable investment reporting and disclosure regulations or internal policies without prior notice to or consent or comment from
the Company (including, for the avoidance of doubt, filings pursuant to Sections 13 and 16 of the 1934 Act). The Company shall not include
the name of any Buyer or any affiliate or investment adviser of such Buyer in any press release or public announcement (which, for the
avoidance of doubt, shall not include any SEC filing to the extent such disclosure is required by SEC rules&nbsp;and regulations) without
the prior written consent of such Buyer. No later than 5:30 p.m.&nbsp;(New York City time) on the first Business Day following the date
this Agreement is executed, the Company will file a Current Report on Form&nbsp;8-K attaching copies of the Transaction Documents. In
addition, the Company will make such other filings and notices in the manner and time required by the SEC or Nasdaq. The Company shall
not, and shall cause each of its officers, directors, employees and agents not to, provide any Buyer with any such material nonpublic
information regarding the Company from and after the filing of the Press Release without the express prior written consent of such Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Signature Page&nbsp;Follows]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>IN WITNESS WHEREOF,</B>
each Buyer and the Company have caused their respective signature pages&nbsp;to this Common Stock Purchase Agreement to be duly executed
as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIQUIDIA
    CORPORATION</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Michael Kaseta</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Michael Kaseta</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUYER:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROGER
    A. JEFFS</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Roger A. Jeffs</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE OF BUYERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(1)<BR>
Buyer</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(2)<BR>
Address</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(3)<BR>
Number of <BR>
    Common <BR>
    Shares <BR>
    Purchased <BR>
    at Closing</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(4)<BR>
Purchase
    Price <BR>
    to be paid at <BR>
    Closing</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left; width: 25%">Roger A. Jeffs</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">c/o Liquidia Corporation <BR>419 Davis
    Drive, Suite&nbsp;100 <BR>Morrisville, NC 27560</TD><TD STYLE="text-align: left; font-size: 10pt; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: right; width: 15%">139,665</TD><TD STYLE="text-align: left; font-size: 10pt; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left; width: 1%">$</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: right; width: 15%">1,000,000</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt; font-weight: bold; text-align: left">TOTAL</TD><TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: right">139,665</TD><TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">$</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: right">1,000,000</TD></TR>
  </TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(See attached)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>lqda-20231212.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaKP2bOdzZR+uYkxtmB6belanywkYdnLayXn7/amYbAL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:lqda="http://liquidia.com/20231212" elementFormDefault="qualified" targetNamespace="http://liquidia.com/20231212">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://liquidia.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="lqda-20231212_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="lqda-20231212_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>lqda-20231212_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>lqda-20231212_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://liquidia.com/role/Cover" xlink:href="lqda-20231212.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://liquidia.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139666807940496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 12,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIQUIDIA CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1710962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">419 Davis Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Morrisville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">328-4400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LQDA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm2332695d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lqda-20231212.xsd" xlink:type="simple"/>
    <context id="AsOf2023-12-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2023-12-12">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-12-12">0001819576</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2023-12-12">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-12-12">2023-12-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-12-12">LIQUIDIA CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-12-12">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-12-12">001-39724</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-12-12">85-1710962</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-12-12">419 Davis Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2023-12-12">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-12-12">Morrisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-12-12">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-12-12">27560</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-12-12">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-12-12">328-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-12-12">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-12-12">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-12-12">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-12-12">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-12-12">Common stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-12-12">LQDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-12-12">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-12-12">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2023-12-12">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MT:92&["9/\7F_*N!*_JM1A.M:K%04-SELRH.8) ]CX(+=&@' RE6"%IA[3*
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M#?#Y4DIS/+$[_/P'FOZ_4$L#!!0    ( $N CE>?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M 5!+ 0(4 Q0    ( $N CE<'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 2X".5P5"]"WM    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ 2X".5YE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " !+@(Y7C\T\2W4$  "L$0  &
M        @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ 2X".5Y^@&_"Q @  X@P   T              ( !MPP  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !+@(Y7EXJ[',     3 @  "P
M@ &3#P  7W)E;',O+G)E;'-02P$"% ,4    " !+@(Y7JL0B%C,!   B @
M#P              @ %\$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M2X".5R0>FZ*M    ^ $  !H              ( !W!$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 2X".5V60>9(9 0  SP,  !,
M             ( !P1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  "Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2332695d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>lqda-20231212.xsd</File>
    <File>lqda-20231212_lab.xml</File>
    <File>lqda-20231212_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2332695d2_8k.htm">tm2332695d2_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2332695d2_8k.htm": {
   "nsprefix": "lqda",
   "nsuri": "http://liquidia.com/20231212",
   "dts": {
    "schema": {
     "local": [
      "lqda-20231212.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lqda-20231212_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lqda-20231212_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2332695d2_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://liquidia.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2332695d2_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2332695d2_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://liquidia.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-23-126023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-126023-xbrl.zip
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MI<OV]"A9B(FP80&S'BV_J2*PE4 BK*A4+@@MPA,L%-'S/'<+Y*D39>AW<V&
MB2,= /]AY13U=ZU<4S#]CR5WC'ZUUB9<W"S]O+Q]35TN%PJPRAIOND7S^[_#
MPTQJ \4\N9;G&I/K!V[=]R8RFF6Z2Q*S-[!;$I:W1Q)K[O)5\>4ZN#ED([1M
MT#7?A(U!5W(@IDI:R]XIS']!_B*'3&:G)!;:&2D!C801#5S=Q[J_/IWWF-FS
MW&L(0IXR)::[#,(\Q3[LUXW9MW^[1EA\W@3S=V#?L'M,037XJA%HPEQ-'_\
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M9$XS898'P0)@RF2@D"&E0X702\_KNP0L4P\Q@LTQ96X)L)ML4M#4!$2"U1A
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M][A5%$3O=SDS22BUJ"EVC,6"TR1*LH2M?Y$GGR+!ME;91*Z @ UJ&MJ*(%
M;9D<'(1(*QU#<">(@I#(CLA? E2)A<3MPX-UMN\2NX*BW["& U8& 4FO/1,6
M&3".:A&H"$%YC%]LYFFZ)>)-\%A"/"$$F@= :NE#Q DRV0M5$>B3K06)MG)^
MW)],5\LDH[:3R[;$V9P$F*MF)*,\"#8 4R8+>1GB#^AD^M?5WY".<MS]-WPI
ML$H>N]AO5IP"V:>L*E<0=%C4'%@D0:  ^S)IN.&HE*)"ZR,[5<.LI3E&N2L
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MAHHPG7<.?-W8#>[]M,4W[I=[!ZO=\C]02P,$%     @ 2X".5UXUC$>K%@
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M4R)V 3Z(0L]V.D_VY*5).T/R^7Q:+8)9+\"BNO!4#_V"&PL6K8.JQ3EX5..
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M']G]V]NZH_T^;6:=<:%ZI1FYAV^2'/\'4$L#!!0    ( $N CE?X#=^D$;H
M +\K!  5    =&TR,S,R-CDU9#)?97@Q+3$N:'1M[+U[<]M6MB?Z/ZOX'7#[
M3G5)59 BV8X3Q[FI*S_2[6K'T;&=TW-J:FH* D$)$0@P>$CA^?1WO?;>:V\
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M0K,$9WH&$ZV*672VHDG+6D6TI$E1P%S]9_\ZGV=U-IM.W$L.Y2UK)$NTYYZ
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MF%:%"F(E?K'!9.A$DL9^X$N5V(_F75WFS873"0KJ8.*SXNX$Q679G_AC@SZ
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ME1>S<5EH77/FISS<"'MEFMZ7;+Y'TP&R+VV.2##>Z42?K#OL+FUO95Y=?7D
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MIU'D7/8G,57+ L!F6<?AO$Z6X.MP?'B![K!K9Y^4H%ZP#A''T&0,/ N715H
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MI+^RFVB8>2LY3[ ]EIX*9C0"/^9)-L3JTR'9.I8;6RE;B!@VE U(%:F<U&_
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M\E*BVD8(*'I\%-'(RNFZP,GR0U24E8QYZXZU%87MO\9D<B5D#TF909&.I9@
M'R@?PG<'2'^N_J+>LZT\&^4\RR[!>.';"5+2P0KPB653#NZI(?(I4HD0/!6^
MFA)3=ME8(Y70)/-6KQ?=7?".2:[#P+(8;"?HNX^S6+S#:!30106R052[M3:M
M'"YWV3VOE)+SL?(WRZ)GE])=SZRN)\06WZ.00X3[.$9*8RQKA8>!28!NAKHX
M43T0; M['UY%3/H]XYDUO0F:;"^MNW"%FZH#*XILJI&<NA2R)<!)W]P(FJG:
M2]=!8=E1RJXC\SW)*_U%"4&L-P!G9=9?^^O>L>/2"LT_'SYFRGW,FI:Y[7N/
M,?>-Z8G9_KH8@"TN<K\LQ^@F;6[(@FK6;.9:5]MB*RE*;3JKCX9&3LD"TA&O
M;(T9@U*^Q$I<7&EE !0F\D[6PA8X*.EH+#RH5C4./Q9/,9JA^@[RU)' =ALS
M'T&]F5F<:!"VD67:;$I"KE^FK#_'I: !K@L$5B\51XK&<LU2XCK">V>1? "K
MCCR[$%L\H/(P7F93V6*;LOAA'>3E12\#OEGWDRYY,?R4Q8;AO1*]?3YXOH?+
M/BAK(*7GU<5@ZRAQV<4^6&PPEEWDJ2N7,+[=,I!R(:[HB9Q2CH53<O3K]JDY
MT=:T.,<(OZ@33*FS>VY_*I;C(J- /7?!"V)N4:U>0XO ZBM$?-Q2/KG(<+"6
M).LWY&*0])CMGN[4# XX> 8U@7RB6$I^=%UCL.J*S3&QTN^C3*5P%I$1N:;]
M0'!1JAB_V'P(_WIEA)\<VBD[: N?7R<"NM4K"XP,P/^D::P_YYBWD>5M<S<K
M\R9FY[;GQ*D6+#/@J!9[>?#(B?A8A577Q>7[&'JQ3/@9.14:\(+#  6V/H1W
M?PA?:Y/3"@<NLH\F></A@]0+/:/;0='DAU90\&)=4/#0"@JL!C,__&7U5(C(
M#U-,H+N*_7*04@BKLU@(+PI$\+8ID( Y*=O+I 14G5(:B\(98ME:WZECCBQR
M@H8"I%4Y(4V>]/&*(X.1_PHN) \ ;&PRF:S*!B=0:8<,MOT&K;]5-:X+*(Z+
MDBX6*]"4]>.("XK=RT(RBG.-D;))9.!S<HX&^V3W9UWU-QFC"T+F/X]@<\/.
M)WG=9"I"-:DNV'W@(/7VPVBF^'-&YPZ($Y@+?OQD<^,R 7^KCJ02P50R4EEF
M+>DFCH8M7H[95F&I\JGPB7;0K,?,5W\>S+KHV*:I+:UY[!2RPLLJZ^H@SL-J
M:_([\(1(T^J,<W9^D)"#RBE5_D>D.V%,HMK-L,/WP'@EE@ON&L# $O\+A"OY
MEK*/*2JKE\I08 =*CB1%0ZKWA:L*SG?2P8J&#EGY7(V!$2Z*FU%BE *[$L[$
MZ@/0#O_1ZA,6*1M-<J=M:%3)[I)IPQ(U];4 O*.?=#&7F% Y!$>L=868W2,:
MZN3A!9NCDX?6HWVUM/7%B_4P9/!/N05+601' W5A/RC>KOM..-FJ*^90)XPI
M;]5+1W")4D' D!!B3(22&S;Y[N*0DVR6VUV*^DZ75/CW6;AY,I8[7<6D3:N8
M%08JTG/0(2QUG71\B0$'6[I4":%=*/@P]M8_$$[WK17U4NK&8E+!X.(@8?T;
MZ=0A7SJ8>H6]UN?:R\%V\4<5_]I?5S*9NU0>8&F=?E4. Q?=K,LQT&Y,*A%M
M-M!!J6JD@YLIRM/S)(\IK@5N..?;LR(I\%:*G6H.?&CR7662:ZH5,A6'(.,I
ML1R/L .]0KNGJ73ZDXH$?=9:PUAR;!@\'X2BMU+<8M>3=0=EB7E!6 55==<%
MGQ2SHI]Y^+B,;V 7HA-LTL'_P'>:&IBCSV=6 (5NV&DY:4M0GG+$1:UV'!@F
M]RJ3X4#S;?1PH^ ,DV\J=N$(C;P=_L?J*0K&&5EWP[,&;*N.I?TWXS36YH8]
MJ:SF:OD>WTOUY/P<5T+?IC[("ALTMAE-=1W?=&C:'_C#5 O\WVB4BRI /V#+
MJ@=$> _6E6B-];,TR"]K9V+I*8@6+C%UWI:(Y;>;TN4\=I.;L5>#J'.KMNE'
M=J> .KC]B>V7Q+89!EUH:(8>@W6)%S^_;G\_CO9W]P^X[#1SAM$&J&#[8EZB
M82Q)7KZ-V'7A2PJT#KF+XI6JCU*VE,V_>R9KK5+J_;*R4S_*1J*MP4*8,TI(
M<RU=+8W$54I;2\>W4:=G!RQS,.Y0=Z$>Q@]+./[G4K4V(VGP,(^#-)!KT E6
MWY>$P3#&(I& <4YW3W\"2S<J+REVD(S 8AT+'_,$M#T9MG-H/+Q20@D:5&Y@
MA%V47:Q:9?4KJ!Q1)V.'NEF-:1HDN!"WQ-) O!GA?]AE3W(/FT2NJQH?$"H*
M?"B[WIH*!#W7S9-LJ*K?,-,ZI8(VC)5.X+@F%1QU6&]]Q-C[89N8TU;F>)WC
M PHIH,,7H(TRKB:LM[QL&U^U>7*I5_Z,G![XA\*C6F%XPC 6W/]UJ/M&FKJO
M7^9Y>5EC5<7_6]TYS1=A?KR[CC#?2H1Y(7CS^5\Z'Q!Z ]Y\_A?,3<*V++*?
MY6!/7XGA?0,KL##X^)/=I3(8:UVU9)[EY8[R]GE\%Q:=-5_[6DD\)"D\K="/
ME=HT9 ="L^R4TV*H- A3<"VBJS39%1W66DT\8"DDHOFU$/Z0>-Q#(2/XR>XM
M[^K6B?0)\*!TV DN)JG7J/EBHOI;^4]*Z-7CLI=Q,PNU!6-UHX^$H)L"M^^5
M."^7WO&N(@I[ZXC"/21QL @0CB1%=RQ9BB^8IEXJX<$L[H6OTAVG"JKO$>V"
MC6C_KJQ4)Y<.B3:Q?$O=+9?5$:$%;VX<$O;!>)P@2#:7(*B<3"8=W#V%VBOM
M4G<<KKH6Y=X=EC,__K%J9JN"$T/E;_\]R2Z2?.'FDE.I7FY6?>H2!"S_;.2/
M+424I\FCO:V.9/UTH=QBP[#[#VZM?'HM7O.(E[TUEI1<IW8>)<DOHG0Z3T#'
M[+TX0-R3FI&@*&&VEH8[EH:9_4M&4IRJP&6)2CTJ)W4(IB@F@)'A,.UA+5'$
M4]%@&2$@LD7;=A9XNBH,E^%Z4'DY5U\K?N)%1A%ZQP!?047BC.M14R5HT<U&
ME(Y&+ 7,B&8-')#F$Q;L1&3T-H1#8',@-3 6:I\J;ZVP($MA8\!9P)RN+$>:
MU^DEYGL1W&#A/C/LYTKPYDIRJV$3T_-8'@;KCN7S8&Z/N1!J2 6P%9;)5EAE
M%T=8AUE6^!'&):L"F\ 6Q_8=CO)RJG#H= /Z]HY%77$2EB+[QDV$;X&ZU?D$
M+#:4Q2[KU+^LU_?O_=2X;K_GLE3NB$'T.BDL5#$#@P,+/+)BPC5KE:[()&P1
MTI$,DK?@H;+>I="B7NS"OZ>UM-?H/XL:-OS@5Y6U+3824P.W/A%W?R(LJ3^=
MC"U_)^3"7$?\%U.A@[4*77&!F5.%_B!D1KA;DI$G1@JY4-<_FCY(TZM%T(Q5
MJF&T%AF'%&$O0 G'<%NT1?@155(J.&C!$^7Q+#@0-@2MIC8]Q4D.=A\L<3Z]
MSN 6W!=N9EJ?OCL_?=8)<SLF;R"$8"('!^O(P0J+0>XP/"VJ<?.6SG1XU,OU
M3L^QTWM40A?>YR<_XUQ[23UXI;>NAB6/I;,92[+IGU34G7!/62T["E98;\5P
MAA[(%@BB.MWQ P28YN[RRG ?< MA%QN,,1W38AHO;%7DQ$TLS36]5#T?QN%E
M&RSK>[W_2]__$;5 QM%@.D(+JRL;<H[&I-OTG:G.Q:Q8/?ZB![(;-J(<0<<:
MI'_%S8!!B5M3A<O,%#OQ:A78U:P1X:;^&^REN==RM1)^+:(A+L/6)BV#9(71
M@) R2H/A8Q$KDR?JL@-;-";8W#HHZ>9:E+Z+"@RXKRL%VZ,<(BE 5G\C&HL
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MZ52U)_%U?GSECSE.&KSZ6(5<(@VB;M<)"S:"$KH3-KJJ(0$* ]Y04"#Z^IA
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M#Y$Q =]F8!'\NVVDOL(;2D.:[ K +\Z+*U2&_#,9.V K3),+7;NFD:_9&/0
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M!C6*J)VBS%.D6I @<D*7)!Q5]-1(^?@H\0BL1OPM+J4L&UPG^*<\':95A6%
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M#-5:5!*7\_RG6%_#CK_4UJB8D)F$'[/0S\#/2S_/LC((]4DS5GD1%5;P9H5
MFA$#I1OVMG2=E78'DPDR+TBL2KY;>6NGV3BW4VR]A 31X5@3[LYH,:/ [@S8
M>137(/9M%#G<-\_K$I._>NPX6.*&B:T7*!C#G"%D,G$+H\9GPH,92<!>A 2?
MX/NRV4ZX&-=AP]0<?"=:XL%,J/&F0FT#L+QDN#4XL(BND%4!:]ICKF;/JDE*
MS=)8'WF+VY9CCQECYY%3U&7>4=JV=G0A^QDMV4X3;O5-[,(-OCY^Z]RH+E6%
M-FE6D>QOM(Y5<)Q"+T /N<U&B(4:GATAMG#K%; -F,Z@H,J34@2\$1 RE0=#
M=%#3D5T-@QW3(H:<\&5TC52VI<HON[L?&YU49C/7)Y.;_U54=L7Z0MI=4/B'
M6ERXYH@CZRQ+?,^5$9G6%]IAM%M<I(2LJ-&+L7K3%IC,\P2T+$ZH\R'X<M/5
ME*1I7!0U/36(.>+LHW4FS.>H/6,"(2592=5\9/8O%]\Z."/@-F==7#-<\TW/
M+3Q?3-4&"DE15Q36=!$8*:E@>2?%5>6>H2.O45O1S1MK.YA67L&OKF7N@&W(
M,=,ZB;%]E$P.KN9%FI2/4D)HPY<,W*0R"GW)5;JRR+UV)"[@XAOX"<K(/(?9
MTQ9$W)P-2[?<'>9(=> KX['5VEUQHT";"W*ZRZMTD8=XV65 U+3T7FFTH]B9
MG T%_&A)_>TX@688AQY'AX6C)_=]<EQQ4$<S6BLT"A:R[ **;Y-$P0K%>RU*
MV@Y)[8^(*^%:8"[J%/[I9]O\.(3?RZGD).477)&5N2!MR21]9OD-J()0:X7?
MVC=@^P),./6Y_!Z\\\[^GZ,=_(FI.I74V'K%2.U:)-I!KO@EB]0_^/YLYNVV
M::86H )Z/RG MA.U\RKZZ#J7[6(LTVGBMZDF(+2SO=W57(H0/!-9[%K=2ZI/
MXL0<W\M*4:HQ)L>QMN<L.1.K*U]PIP70#HK+K\P0"7HAOZ?*[3JC"VP#E:A(
M'Q9Y2Z+TV!F@T9O.QNBU@E I@+NT+I+,;7\W^@9O%/*-QBGY_,WX]T+^@*B$
MLKA(/4)_Z S>*BA2&2.PA9?,+\N2MN@N*MUH7"DOWPRJ$W$W2EXJO&K6Q%D1
M_JEKR58OE!,,QE+/$HFN4QFA"2?#-Z;4)5 J/F*IAI12C5CZ;)?,XYE7Z;58
MKZ2NL7+7FQ"X 1QZF=>/BO&C63'$XF-Y'N)X954Z)NH<YN$DR:8-,( 2CNDF
M$=BD(18.9,P_KA*_:*7TW7F]N%Y$^^5#1/N&(]HO'R+:=_%ZO]T>ZWB](TGN
M&<<YCZ0?]>K[VZ0VO_@:1V6XM+@<HX32UYLT7:6JKG)!2:EMH#_P72\*5;Z
M0;CY(OBL1L.;G4.36I!W$G,(<#<N!F7AP$OK6;IZ1EV=I[)Z93$_.Z?R]S,+
MVN+XJ[8 ]WP*5U3]08C/>96*B[:R4SCC GD2CI2QD'ZH6G74<$J;^( @Z"H[
MZ:-Y_9YYEG^'[XQ[K9?JEV@U<)/I-WVU2S('94+"";=T+7M3+2JP/U"VA.[#
M;XR!IS5C-R6ZDU7-J*=1REVS4P[EN(??_0OTIC3/Q>V"G%BVW%D[32Y2! Y&
M'\NB%N+15ZWB_VYJ,U?P'-8[D^,H+$<(VG=1"#9C?;9,HQ*4M2E3DE0PT$TL
MFT&;=5E,^%#!(Y@/02(PS&Q!03E77!U;=BU#I3,K,M2/,RPDN,9(Y4S%"+52
M-IB;\KC$E0OJRFR:.C4!Q&!YWZ-:U]6=57,45U4 Q!$C[<FHY@<O[^<0$K_A
MOYO$;[A'/D[E@E\$Q;1X^@"O[7T73/I0,S\$/U_KDK1Y9]:@&KBNV%8P/P%D
M!E;&LJU=X^/<I*Q&W:+*$F.D4 6%J,)-X2V5?YZQ"V*]/ZPAG5J%W$2;Z5R7
MU4HF0O"D#B$=FE 5WQ\=.[E='3NH4E=@+MSQ>\R^Q8K4Q^6$^&E)!!K4&!R+
M-R"4V&J=U_K)=ASM;.WL:"[ H;3RHLV8IR+!R=KVWT?I93HI9E/Q?7$ GDVO
MDT'/4NQ9-KWK.?-BU2/-[ QAGPO)!S4D]N:6RM?@:%S 05%'Z7!".44<"1>3
MH_;') -V3@VJG"KF65JXU;F^X0DF/C\/A0K\O[:WMN*MK2T0CGE=P1L<G0Y"
MC5'S()R?<TZZ%6UD"PY?M!:IG73&B8 TO<"UE(L\P(4DW)F&=!%H7ZS)4OU#
M]^^ZM!F24")]U"+.N!(>D?F,_1(*)M?!X"6H;/"V6G;#PT@G67J91I8S#W6W
M8]"@6U^H?'*0.+Q#*?4XSVM</C\/7(EA2LB5RIG6PQIV*D3[DEF.^1(I2E+O
MQ)4"82(#]:L,03A#JR+<%TDI+26NCJ7;Q1F(BZ<65/:T97<JB"L#2C%"B#P#
M#?:)V%=&#E*P)'CCZ@ "S2S7C[$BI>%[+"/J=,\Q67#P$E/JPM#,%WKG,PZ)
M.37YB[E@\B?)OD"P:.H -/Q%%PSD4X5K25%'5].?3#&-[]+4)"JS9-'YC+I
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MP,=?)H*$]C'#BIEP)!;<F^GTAU@G_MTX&2J,R512NL^%4'7;03@E<.407QL
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M=;O7HR+.W"25@+-\MS"9TC1S-YG R34X+,!>&J'."R7[K=D-U"Q4*F]EP>U
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M751I$I(.!O@+.>J%[[LMF7W0X4C+G48G5,_8?)-\"A,A]+&@!.(;%Z6XRB4
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MSS7W]+8WM4RQW2CVL_+M7:^HX(\".N1)!!8Z)Z6#R)LS\.M2K"9IX=9-4LG
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M,J)S8F6IYI-:GPBKE)7P<>Y'545GV27.J\RX)X1GJO4PNB]=+.=%/O[NQ.^
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M$K!#J!A7F)F%STS!LS<7*I!D.@,H@4&!!]"_9A!OUWJ(?,@1%@YJZ"%PFQ(
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M2_P*ZK]02P$"% ,4    " !+@(Y7NYC#_B@#  #C"P  $0
M@ $     ;'%D82TR,#(S,3(Q,BYX<V102P$"% ,4    " !+@(Y7_K- ]?T*
M  " A@  %0              @ %7 P  ;'%D82TR,#(S,3(Q,E]L86(N>&UL
M4$L! A0#%     @ 2X".5_*Q3EI6!P  U5<  !4              ( !APX
M &QQ9&$M,C R,S$R,3)?<')E+GAM;%!+ 0(4 Q0    ( $N CE=>-8Q'JQ8
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H,S,R-CDU9#)?97@U+3$N:'1M4$L%!@     '  < SP$  %A^ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
